

RECOMENDACIÓN 5

BÚSQUEDA Y SÍNTESIS DE EVIDENCIA DE EFECTOS DESEABLES E INDESEABLES Guía de Práctica Clínica Influenza - 2018

A. PREGUNTA CLÍNICA

En niños y adolescentes menores de 18 años con sospecha o diagnóstico de influenza hospitalizado ¿Se debe usar oseltamivir en comparación a no usar?

Análisis y definición de los componentes de la pregunta en formato PICO

Población: Niños y adolescentes menores de 18 años con sospecha o diagnóstico de influenza hospitalizado.

Intervención: Oseltamivir.

Comparación: No usar oseltamivir.

Desenlace (outcome): Mortalidad, neumonía, náuseas y vómitos.

B. BÚSQUEDA DE EVIDENCIA

Se realizó una búsqueda general de revisiones sistemáticas asociadas al tema de “Influenza”. Las bases de datos utilizadas fueron: Cochrane database of systematic reviews (CDSR); Database of Abstracts of Reviews of Effectiveness (DARE); HTA Database; PubMed; LILACS; CINAHL; PsycINFO; EMBASE; EPPI-Centre Evidence Library; 3ie Systematic Reviews and Policy Briefs Campbell Library; Clinical Evidence; SUPPORT Summaries; WHO institutional Repository for information Sharing; NICE public health guidelines and systematic reviews; ACP Journal Club; Evidencias en Pediatría; y The JBI Database of Systematic Reviews and implementation Reports. No se aplicaron restricciones en base al idioma o estado de publicación. Dos revisores de manera independiente realizaron la selección de los títulos y los resúmenes, la evaluación del texto completo y la extracción de datos. Un investigador experimentado resolvió cualquier discrepancia entre los distintos revisores. En caso de considerarse necesario, se integraron estudios primarios.¹

Seleccionadas las revisiones sistemáticas o estudios primarios asociados a la temática, se clasificaron en función de las potenciales preguntas a las que daban respuesta. Al momento de definir la pregunta, la evidencia ya se encontraba previamente clasificada según intervenciones comparadas. Los resultados se encuentran alojados en la plataforma Living Overview of the Evidence (L·OVE), sistema que permite la actualización periódica de la evidencia.

¹ Para revisar la metodología, las estrategias y los resultados de la búsqueda, favor revisar el informe “Búsqueda sistemática de evidencia de los efectos deseables e indeseables” en la sección de método de la Guía de Práctica Clínica respectiva.

C. SÍNTESIS DE EVIDENCIA

Resumen de la evidencia identificada

Se identificaron 33 revisiones sistemáticas que incluyeron 376 estudios primarios, de los cuales 85 corresponden a ensayos aleatorizados. Para más detalle ver “*Matriz de evidencia*”², en el siguiente enlace: [Inhibidores de neuraminidasa para influenza](#).

Tabla 1: Resumen de la evidencia seleccionada

Revisión Sistemática	33 [1-33].
Estudios primarios	85 ensayos aleatorizados [34-118], 291 observacionales [119-409].

Estimador del efecto

Se realizó un análisis de la matriz de evidencia, sin identificar revisiones que hayan analizado la población de interés (hospitalizados), ya sea de manera directa o a través de análisis de subgrupo. Con el fin de informar la decisión de manera indirecta (evidencia de tratamiento en cualquier contexto, no solo hospitalizados), se seleccionó una revisión sistemática que incluye la mayor proporción del total de estudios pertinentes identificados en la matriz [18]. De los ensayos que esta revisión no incluye, la gran mayoría no son relevantes para la pregunta, por las siguientes razones:

- Se administró el inhibidor de neuraminidasa en conjunto con otras intervenciones [33, 112].
- Comparan un inhibidor de neuraminidasa contra otro [34, 37, 49, 50, 51, 87, 108, 109, 111].
- Comparan biterapia con dos inhibidores de neuraminidasa versus monoterapia [40].
- Comparan diferentes dosis del mismo inhibidor de neuraminidasa [36, 52, 57].
- Compara inhibidor de neuraminidasa con ribavirina [107].
- No corresponden a ensayos sobre tratamiento [53, 84, 105].
- Modelo experimental de influenza en voluntarios sanos [41, 48, 110].
- Por último, se excluyó un ensayo de peramivir versus placebo en hospitalizados, que si bien se trata del único ensayo evaluando inhibidores de neuraminidasa versus placebo en la población exacta de interés [35], se consideró que se trata de una intervención no representativa de la intervención de interés para este informe (oseltamivir).

Algunas revisiones mencionan ensayos no incluidos en la revisión Cochrane 2014 [18], la gran mayoría realizados en China o Japón, y no fue posible determinar si efectivamente constituyen ensayos diferentes u otras publicaciones de los ensayos incluidos en la revisión Cochrane [32, 38, 54, 58, 59, 86, 88, 113, 114, 115]. Considerando que se trata de ensayos pequeños, es improbable que su inclusión lleve a diferencias sustantivas en las conclusiones de este informe.


² **Matriz de Evidencia**, tabla dinámica que grafica el conjunto de evidencia existente para una pregunta (en este caso, la pregunta del presente informe). Las filas representan las revisiones sistemáticas y las columnas los estudios primarios que estas revisiones han identificado. Los recuadros en verde corresponden a los estudios incluidos en cada revisión. La matriz se actualiza periódicamente, incorporando nuevas revisiones sistemáticas pertinentes y los respectivos estudios primarios.

En vista de lo anterior, se decidió utilizar los metanálisis de la revisión Cochrane [18] para construir la tabla de resumen de resultados.

También se identificó una revisión analizando estudios observacionales de pacientes hospitalizados durante la epidemia de influenza A/H1N1 durante 2009-2010 [25]. Debido a que esta evidencia también podría informar de manera indirecta la decisión clínica pertinente a este informe, se decidió agregar también el estimador del efecto obtenido por esta revisión en la tabla de resumen de resultados. Sin embargo, se decidió disminuir certeza adicional, ya que proviene de estudios de adultos.

Metanálisis

Neumonía



Náuseas y vómitos




Tabla de Resumen de Resultados (Summary of Findings)

OSELTAMIVIR PARA INFLUENZA EN NIÑOS Y NIÑAS HOSPITALIZADOS						
Pacientes	Niños y niñas con sospecha o diagnóstico de influenza hospitalizado.					
Intervención	Oseltamivir.					
Comparación	No usar.					
Desenlaces	Efecto relativo (IC 95%)	Efecto absoluto estimado*			Certeza de la evidencia (GRADE)	Mensajes clave en términos sencillos
	-- Estudios/pacientes	SIN oseltamivir	CON oseltamivir	Diferencia (IC 95%)		
Mortalidad A partir de NO hospitalizados	Los ensayos de oseltamivir no detectaron muertes por influenza, reflejando la naturaleza benigna de la influenza en la población. Los ensayos de zanamivir detectaron 8 muertes, de las cuales 2 se relacionan con influenza, ambas en el grupo intervención. La mortalidad en Japón durante el brote de A/H1N1 en el 2009 fue 198 en 20 millones de pacientes (1 de cada 100.000) [18].				--	--
Mortalidad A partir de estudios en influenza A(H1N1)	OR 0,72 (0,51 a 1,01) -- 20 estudios [121, 142, 152, 175, 179, 183, 186, 218, 219, 276, 299, 307, 325, 338, 345, 347, 395, 396, 398, 403]	8 por 1000	6 por 1000	Diferencia: 2 menos (0 a 4 menos)	Muy baja	Oseltamivir podría disminuir la mortalidad en niños y niñas hospitalizados. Sin embargo, existe considerable incertidumbre dado que la certeza de la evidencia es muy baja.
Neumonía	RR 1,06 (0,62 a 1,83) -- 3 ensayos / 1359 pacientes [86, 99, 100]	37 por 1000	39 por 1000	Diferencia: 2 más (14 menos a 30 más)	Muy baja	Oseltamivir podría tener poco impacto en el riesgo de neumonía en niños y niñas hospitalizados. Sin embargo, existe considerable incertidumbre dado que la certeza de la evidencia es muy baja.
Náuseas y vómitos	RR 0,56 (0,26 a 1,21) -- 2 ensayos / 737 pacientes [64, 70]	47 por 1000	27 por 1000	Diferencia: 20 menos (35 menos a 10 más)	Muy baja	Oseltamivir podría disminuir el riesgo de náuseas y vómitos en niños y niñas hospitalizados. Sin embargo, existe considerable incertidumbre dado que la certeza de la evidencia es muy baja.

IC 95%: Intervalo de confianza del 95%.

RR: Riesgo relativo.

GRADE: Grados de evidencia Grading of Recommendations Assessment, Development and Evaluation.

* El **riesgo SIN oseltamivir** está basado en el riesgo del grupo control en los estudios, excepto para el desenlace mortalidad a partir de estudios en influenza A(H1N1), en que el riesgo se estimó de una revisión sistemática evaluando específicamente este riesgo a nivel global [410]. El **riesgo CON oseltamivir** (y su intervalo de confianza) está calculado a partir del efecto relativo (y su intervalo de confianza).

¹ Diseño observacional.

² Se disminuyó un nivel de certeza de evidencia por sospecha de sesgo de publicación identificado por la revisión sistemática cochrane.

³ Se decidió disminuir por riesgo de sesgo, ya que solo 2 estudios ajustaron por variables confundentes.

⁴ Se disminuyó un nivel de certeza por inconsistencia (12 49%).

⁵ Se disminuyó dos nivel de certeza de evidencia por indirecto, ya que la evidencia proviene de pacientes adultos y no hospitalizados.

⁶ Se disminuyó un nivel de certeza de evidencia por riesgo de sesgo por limitaciones importantes en la mayoría de los ensayos en diversos aspectos (generación de secuencia, ocultamiento, seguimiento, ciego, reporte selectivo)

⁷ Se disminuyó un nivel de certeza de evidencia por indirecto, ya que proviene de niños no hospitalizados.

⁸ Se disminuyó un nivel de certeza de evidencia por imprecisión, ya que cada extremo del intervalo de confianza conlleva decisión diferente

Fecha de elaboración de la tabla: Octubre, 2018.

Referencias

1. Boikos C, Caya C, Doll MK, Kraicer-Melamed H, Dolph M, Delisle G, Winters N, Gore G, Quach C. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. *The Journal of antimicrobial chemotherapy*. 2017;72(6):1556-1573.
2. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood M, Palmer S, Stewart L. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. *The Lancet. Infectious diseases*. 2009;9(9):537-45.
3. Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton NJ, Ades AE, Sutton A, Cooper N, Elliot AJ, Nicholson K, Duffy S, McKenna C, Stewart L, Westwood M, Palmer S. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. *Health technology assessment (Winchester, England)*. 2009;13(58):1-265, iii-iv.
4. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. *BMJ (Clinical research ed.)*. 2003;326(7401):1235.
5. Dobson J., Whitley R.J., Pocock S., Monto A.S.. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. *The Lancet*. 2015;385((Dobson J.; Pocock S.) Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK):1729-37.
6. Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. *Family practice*. 2013;30(2):125-33.
7. Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Rello J. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. *The Journal of antimicrobial chemotherapy*. 2010;65(7):1330-46.
8. Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. *Health technology assessment (Winchester, England)*. 2016;20(42):1-242.
9. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;53(3):277-9.
10. Higashiguchi M, Matsumoto T, Fujii T. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. *Antiviral therapy*. 2018;23(2):157-165.
11. Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyan G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smaill F, Schünemann HJ. Antivirals for Treatment of Influenza: A Systematic Review and Meta-analysis of Observational Studies. *Annals of internal medicine*. 2012;156(7):512-24.
12. Husereau D R, Brady B, McGeer A. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment. Ottawa, ON, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report; 21. 2001;

13. Jagannath, Vanitha A, Asokan, G V, Fedorowicz, Zbys, Lee, Tim WR. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews*. 2016;2:CD008139
14. Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, Nicholson KG. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. *The Journal of infection*. 2011;62(1):14-25.
15. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. *Lancet*. 2006;367(9507):303-13.
16. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ (Clinical research ed.)*. 2009;339(7734):b5106.
17. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ (Clinical research ed.)*. 2014;348(no pagination):g2545.
18. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews*. 2014;4(4):CD008965.
19. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. *Archives of internal medicine*. 2003;163(14):1667-72.
20. Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. *Annals of internal medicine*. 2009;151(7):464-73.
21. Langley JM, Faughnan ME. Prevention of influenza in the general population. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2004;171(10):1213-22.
22. Lee J., Park J.-H., Jwa H., Kim Y.H.. Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: Systematic review and meta-analysis. *Yonsei Medical Journal*. 2017;58(4):778-785.
23. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2018;66(10):1492-1500.
24. Mizumoto K, Nishiura H, Yamamoto T. Effectiveness of antiviral prophylaxis coupled with contact tracing in reducing the transmission of the influenza A (H1N1-2009): a systematic review. *Theoretical biology & medical modelling*. 2013;10:4.
25. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009-2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients. *The Journal of infectious diseases*. 2013;207(4):553-63.
26. Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. *PloS one*. 2014;9(12):e113633.

27. Osterhaus ADME, Hedrick JA, Henrickson KJ, Mäkelä MJ, Webster A, Keene ON. Clinical Efficacy of Inhaled Zanamivir for the Treatment of Patients with Influenza B Virus Infection. *Clinical Drug Investigation*. 2000;20(4):223-228.
28. Qiu S, Shen Y, Pan H, Wang J, Zhang Q. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. *Infectious diseases (London, England)*. 2015;47(11):808-19.
29. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. *BMJ (Clinical research ed.)*. 2009;339(7718):b3172.
30. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. *Health technology assessment (Winchester, England)*. 2009;13(11):iii, ix-xii, 1-246.
31. Toovey S, Dutkowski R, Smith P, Smith JR. Oseltamivir effectiveness in seasonal influenza patients taking symptomatic therapy: retrospective analysis of RCT data. *International journal of clinical pharmacology and therapeutics*. 2013;51(12):932-41.
32. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modeling for the prevention and treatment of influenza A and B. *Health technology assessment (Winchester, England)*. 2003;7(35):iii-iv, xi-xiii, 1-170.
33. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). *Cochrane Database of Systematic Reviews*. 2012;4(4):CD002744.
34. 167-101. GSK. Investigation of the efficacy of GG167 (zanamivir) in the treatment of influenza viral infections (late Phase II study: dose comparison study). Information reported in a systematic review.
35. Aoki FY, Fleming DM, Griffin AD, Lacey LA, Edmundson S. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. *Zanamivir Study Group. Pharmacoeconomics*. 2000;17(2):187-95.
36. Aver'ianov AV, Babkin AP, Bart Bla, Volchetskiĭ AL, Minina ES, Kozyrev OA, Kostinov MP, Petrov DV, Sel'kova EP, Putilovskiĭ MA, Nechaev VB, Epshteĭn OI, Andrianova EN. [Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial]. *Antibiotiki i khimioterapiia (Antibiotics and chemotherapy)*. 2012;57(7-8):23-30.
37. BCX1812-201. Ison MG, Hui DS, Clezy K, O'Neil BJ, Flynt A, Collis PJ, Simon TJ, Alexander WJ. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. *Antiviral therapy*. 2013;18(5):651-61.
38. BCX1812-301. de Jong MD, Ison MG, Monto AS, Metev H, Clark C, O'Neil B, Elder J, McCullough A, Collis P, Sheridan WP. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;59(12):e172-85.
39. BCX1812-303. Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O'Riordan W, O'Neil B, Playford EG, Rolf JD, Sada-Diaz E, Elder J, Collis P, Hernandez JE, Sheridan WP. Intravenous peramivir for treatment of influenza in hospitalized patients. *Antiviral therapy*. 2014;19(4):349-61.

40. BIVIR - AOM06060 - P060209. Carrat F, Duval X, Tubach F, Mosnier A, Van der Werf S, Tibi A, Blanchon T, Lepout C, Flahault A, Mentré F, BIVIR study group. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. *Antiviral therapy*. 2012;17(6):1085-90.
41. Deng WW, Li QY, Zhong NS, "Oseltamivir in the treatment of suspected influenza patients" Study Group. [A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients]. *中华医学杂志 (Chinese Medical Journal)*. 2004;84(24):2132-6.
42. ETOPOM - MV21118. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Vahlberg T, Ziegler T, Ikonen N, Puhakka T, Heikkinen T. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;51(8):887-94.
43. Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp M, Gaillard S, Duval X, Blanchon T, Lepout C, Gueyffier F, Van Der Werf S, Lina B. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. *Antiviral research*. 2012;96(2):130-7.
44. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. *JAMA*. 1999;282(13):1240-6.
45. ICDDR,B. Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. *The Lancet. Infectious diseases*. 2014;14(2):109-18.
46. JNAI-01. GSK. Investigation of the efficacy of CG167 in the treatment of influenza viral infections (phase II study) (Protocol NoJNAI-01). Double blind, double dummy, randomized, placebo controlled, parallel group, multicenter study to investigate safety and route of administration of CG167 when inhaled, CG167 10 mg, or the combination of inhaled CG167 10 mg plus intranasal CG167 6.4 mg, administered twice daily for 5 days in the treatment of influenza A and B viral infections. Information reported in a systematic review.
47. JNAI-04. GSK. A multicenter two way layout randomized placebo-controlled double-blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No. JNAI-04). Information reported in a systematic review.
48. JNAI-07. GSK. A multicenter two way layout randomized placebo-controlled double-blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No.JNAI-07). Information reported in a systematic review.
49. JV15823. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial]. *Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases*. 2000;74(12):1044-61.

50. JV15824. Phase 3 study for prophylaxis of influenza with Ro64-0796. Information reported in a systematic review.
51. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial]. *Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases*. 2000;74(12):1062-76.
52. Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, Ishida K. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2013;19(4):740-9.
53. Kashiwagi S, Watanabe A, Ikematsu H, Uemori M, Awamura S, Laninamivir Prophylaxis Study Group. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2016;63(3):330-7.
54. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J, S-021812 Clinical Study Group. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. *Antimicrobial agents and chemotherapy*. 2011;55(6):2803-12.
55. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J, S-021812 Clinical Study Group. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. *Antimicrobial agents and chemotherapy*. 2011;55(11):5267-76.
56. Li L, Cai B, Wang M, Zhu Y. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. *Chinese medical journal*. 2003;116(1):44-8.
57. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, Wu XD, Gao H, Huo ZL, Zhu SH, Hu SL, Wang AX. [A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population]. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2004;27(7):455-9.
58. M76001. Treanor JJ. Reduction in the symptoms and complications of influenza A and B in patients treated with oseltamivir. 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans. 2000;:Abstract 611.
59. ML16369. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate in the treatment of influenza infection in China. Information reported in a systematic review.
60. ML22789. Durigon EL, Thomazelli LM, Oliveira DBL et al.. Virological response to standard- and double-dose oseltamivir treatment in patients with pandemic (H1N1) 2009 influenza. A prospective randomized trial. *Infectious Diseases in Clinical Practice*. 2013;21(6):373-375.
61. Markovski V, Milenkovic Z, Dimzova M, Tosevski B. Clinical experience in the treatment of flu patients with oseltamivir during the interpandemic period. *Probl Infect Parasitic Dis*. 2002;30:21-22.
62. Matsumoto K, Ogawa N, Nerome K, Numazaki Y, Kawakami Y, Shirato K, Arakawa M, Kudoh S, Shimokata K, Nakajima S, Yamakido M, Kashiwagi S, Nagatake T. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. *Antiviral therapy*. 1999;4(2):61-8.

63. NAI30008. Murphy, K R, Eivindson, A, Pauksens, K, Stein, W J, Tellier, G, Watts, R, Léophonte, P, Sharp, S J, Loeschel, E. Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study. *Clinical Drug Investigation*. 2000;20(5):337-349.
64. NAI30009. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. *The Pediatric infectious disease journal*. 2000;19(5):410-7.
65. NAI30010. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. *The New England journal of medicine*. 2000;343(18):1282-9.
66. NAI30011. A randomised, double-blind, placebo-controlled study to evaluate the impact of inhaled zanamivir treatment on workplace attendance due to influenza A and B infections. Information reported in a systematic review.
67. NAI30012. GlaxoSmithKline. A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged \geq 65 Years. GSK Study Register. 2014;
68. NAI30015. Puhakka T, Lehti H, Vainionpää R, Jormanainen V, Pulkkinen M, Sharp S, Kerr C, Dempsey M, Ring CJ, Ward C, Tisdale M. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. *Scandinavian journal of infectious diseases*. 2003;35(1):52-8.
69. NAI30020. GlaxoSmithKline. NAI30020: a double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled Zanamivir (10 mg bd via Diskhaler), for 5 days, in high risk patients with symptomatic Influenza A and/or B infection. GSK Study Register. 2009;
70. NAI30028. A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic influenza A and / or B infection. Information reported in a systematic review.
71. NAI30031. Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. *The Journal of infectious diseases*. 2002;186(11):1582-8.
72. NAI30034. LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. *Clinical therapeutics*. 2007;29(8):1579-90; discussion 1577-8.
73. NAIA/B2009. Kaiser L, Henry D, Flack NP, Keene O, Hayden FG. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2000;30(3):587-9.
74. NAIA2005. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K. Efficacy and safety of the neuraminidase

- inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. *The New England journal of medicine*. 1997;337(13):874-80.
75. NAIA2006. A double-blind, randomised, placebo-controlled multicentre study to investigate the efficacy and safety of zanamivir therapy in the prevention of progression of influenza A and B viral infections. Information reported in a systematic review.
 76. NAIA2008/NAIB2008. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON, Man CY. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. *The Journal of infectious diseases*. 1999;180(2):254-61.
 77. NAIA3002. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. *The Journal of infectious diseases*. 2000;181(4):1471-4.
 78. NAIA3003. Gravenstein S, Drinka P, Osterweil D, Schilling M, Krause P, Elliott M, Shult P, Ambrozaitis A, Kandel R, Binder E, Hammond J, McElhane J, Flack N, Daly J, Keene O. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. *Journal of the American Medical Directors Association*. 2005;6(6):359-66.
 79. NAIA3004. Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L, Stikleryte A, Crawford C, Elliott M, Shult P. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. *Journal of the American Medical Directors Association*. 2005;6(6):367-74.
 80. NAIA3005. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. *JAMA : the journal of the American Medical Association*. 1999;282(1):31-5.
 81. NAIB2005. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. *The New England journal of medicine*. 1997;337(13):874-80.
 82. NAIB2006. A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir in preventing progression of influenza A and B viral infections. Information reported in a systematic review.
 83. NAIB2007. Perich R, Solterbeck A, Keene O, Leong J, Raniga K, MacLeod A. A double-blind, randomised, placebo-controlled, parallel-group, multi-centre study to investigate the efficacy and safety of inhaled and inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections. Information reported in a systematic review.
 84. NAIB3001 - MIST. MIST investigators. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. *Lancet*. 1999;352(9144):1877-81.
 85. NAIB3002. Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. *The Journal of infection*. 2000;40(1):42-8.

86. NV16871. A double-blind, randomized, stratified, placebo-controlled study of oseltamivir in the treatment of influenza in children with asthma. Information reported in a systematic review.
87. Nakano T, Ishiwada N, Sumitani T, Uemori M, Isoke K, Laninamivir Prophylaxis Study Group. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children. *Pediatrics*. 2016;138(6).
88. PE-01. A trial to investigate efficacy to reduce development of influenza symptoms in influenza infected patients treated with GG167 (protocol number PE-01 phase II clinical trial). A double-blind double-dummy, randomized, placebo-controlled, parallel group, multicenter study to investigate the efficacy reducing development of influenza symptoms and, safety and rout of administration of GG 157 when orally inhaled GG 167 10 mg, 6.4 mg nebulized intranasally or the combination of inhaled GG167 10 mg plus intranasal GG167 6.4 mg was administered twice day for 5 days in the treatment of influenza A and B viral infections. Information reported in a systematic review.
89. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. *The Pediatric infectious disease journal*. 2005;24(10):931-2.
90. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. *Antimicrobial agents and chemotherapy*. 2010;54(6):2575-82.
91. Tan W, Hou J, Chen X, Xiong H, Li XQ, Zhang H. A randomized, double-blinded and controlled clinical evaluation of oseltamivir in the treatment of influenza. *中国临床医学 (Chinese Journal of Clinical Medicine)*. 2002;9:528-531.
92. WV15670. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. *Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet*. 2000;355(9218):1845-50.
93. WV15671. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. *US Oral Neuraminidase Study Group. JAMA : the journal of the American Medical Association*. 2000;283(8):1016-24.
94. WV15673. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *The New England journal of medicine*. 1999;341(18):1336-43.
95. WV15697. Hayden FG, Jennings L, Robson R, Schiff G, Jackson H, Rana B, McClelland G, Ipe D, Roberts N, Ward P. Oral oseltamivir in human experimental influenza B infection. *Antiviral therapy*. 2000;5(3):205-13.
96. WV15707. Grosse M.. A multi-center, randomized, double-blind, placebo-controlled, parallel group study of oseltamivir treatment in elderly patients with influenza. Information reported in a systematic review.
97. WV15708. No authors listed.. A double-blind randomised placebo controlled study of Ro 64-0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season. Information reported in a systematic review.
98. WV15730. Center for Drug Evaluation and Research, Food and Drug Administration. Treatment trials of naturally acquired influenza: 8.3 Protocol WV 15730. Treatment trials of

- naturally acquired influenza: 8.3 Protocol WV 15730. In: Medical officer review of NDA 21-087 Tamiflu™ (oseltamivir) in the treatment in influenza. 1999;:42-5.
99. WV15758. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Oral oseltamivir treatment of influenza in children. *The Pediatric infectious disease journal*. 2001;20(2):127-33.
 100. WV15759/WV15871. Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. *The Pediatric infectious disease journal*. 2005;24(3):225-32.
 101. WV15799. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. *JAMA : the journal of the American Medical Association*. 2001;285(6):748-54.
 102. WV15812. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. *International Congress Series*. 2001;1219:807-811.
 103. WV15819. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. *International Congress Series*. 2001;1219:807-811.
 104. WV15825. Peters PH, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, von Planta TA, Ward P. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. *Journal of the American Geriatrics Society*. 2001;49(8):1025-31.
 105. WV15872. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. *International Congress Series*. 2001;1219:807-811.
 106. WV15876. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. *International Congress Series*. 2001;1219:807-811.
 107. WV15978. Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. *International Congress Series*. 2001;1219:807-811.
 108. WV16193. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. *The Journal of infectious diseases*. 2004;189(3):440-9.
 109. WV16277. No authors listed.. A double-blind, randomised, stratified, placebo-controlled study of oseltamivir in the treatment of influenza infection in patients. Information reported in a systematic review.
 110. Wang Z, Li X, Li D, Li Y. Clinical features of 167 children with the novel influenza A (H1N1) virus infection in Xi'an, China. *The Turkish journal of pediatrics*. 2012;54(2):99-104.
 111. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;51(10):1167-75.

112. Watanabe A. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2013;19(1):89-97.
113. Webster A, Boyce M, Edmundson S, Miller I. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. *Clinical pharmacokinetics*. 1999;36 Suppl 1:51-8.
114. Yoshino Y, Seo K, Koga I, Kitazawa T, Ota Y. Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial. *Infectious diseases (London, England)*. 2017;49(5):417-419.
115. 刘友德, 邹志强, 郭砚梅, 李艳芳, 马斌, 李刚. A randomized controlled study with oseltamivir and modified maxingshi sweet soup therapy for the treatment of H1N1 influenza. *中华传染病杂志 (Chinese Journal of Infectious Diseases)*. 2011;39(9):565-569.
116. 姚彬, 朱小玉, 伍月宏, 武红莉, 田瑞雪, 陈丽静, 王秀云, 林江涛, 陈旭岩, 倪安平. Clinical analysis of oseltamivir phosphate in the treatment of suspected influenza patients. *中国呼吸与危重监护杂志 (Chinese Journal of Respiratory and Critical Care Medicine)*. 2005;4(4):291-294.
117. 陈旭岩, 谭伟, 汪波, 于净, 简忠, 冯莉莉. A Randomized and Controlled Clinical Evaluation of Oseltamivir in the Treatment of Influenza. *中国全科医学 (Chinese General Practice)*. 2007;10(4):272-274.
118. 龙云铸, 李丹, 傅京力, 谭英征, 赵韵华. Efficacy and Safety of Oseltamivir in the Treatment of Patients with Influenza a (H1N1). *中國感染控制雜誌 (Medical Journal of National Defending Forces in Southwest China)*. 2010;9(4):241-244+.
119. AKINCI, ESRAGÜL, Kayaaslan, Bircan, Yetkin, Meltem Arzu, Yilmaz, Sevim, ALIRAVCI, İŞİL DENİZ, YILDIZ, SÜMEYYE, ÜLGEN, FATMANUR, Eren, Selim Sirri, BUT, AYŞE, Yilmaz, Guelruhsar. Analysis of 113 hospitalized patients with confirmed 2009 influenza A (H1N1) virus infection. *Turkish Journal of Medical Sciences*. 2011;41(3):507-514.
120. Adisasmito W, Chan PK, Lee N, Oner AF, Gasimov V, Aghayev F, Zaman M, Bamgboye E, Dogan N, Coker R, Starzyk K, Dreyer NA, Toovey S. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. *The Journal of infectious diseases*. 2010;202(8):1154-60.
121. Altmann M, Fiebig L, Soyka J, von Kries R, Dehnert M, Haas W. Severe cases of pandemic (H1N1) 2009 in children, Germany. *Emerging infectious diseases*. 2011;17(2):186-92.
122. Anovadiya AP, Barvaliya MJ, Shah RA, Ghori VM, Sanmukhani JJ, Patel TK, Tripathi CB. Adverse drug reaction profile of oseltamivir in Indian population: A prospective observational study. *Indian journal of pharmacology*. 2011;43(3):258-61.
123. Aquino-Esperanza J, Rodríguez PO, Boughen S, Raimondi A, Attie S, Maskin P, Bonelli I, Valentini R. [Severe respiratory disease in an intensive care unit during influenza A(H1N1) 2009 pandemia]. *Medicina*. 2010;70(5):401-7.
124. Bagdure D, Curtis DJ, Dobyns E, Glodé MP, Dominguez SR. Hospitalized children with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for admission to the ICU. *PLoS one*. 2010;5(12):e15173.

125. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. *Current medical research and opinion*. 2007;23(3):523-31.
126. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. *The New England journal of medicine*. 2009;361(23):2296-7.
127. Bellei NC, Cabeça TK, Carraro E, Goto JM, Cuba GT, Hidalgo SR, Burattini MN. Pandemic H1N1 illness prognosis: evidence from clinical and epidemiological data from the first pandemic wave in São Paulo, Brazil. *Clinics (Sao Paulo, Brazil)*. 2013;68(6):840-5.
128. Bhatt KN, Jethw SC, Bhadiyadar D, Patel D, Joshi K. Study of clinical profile in patients with H1N1 influenza in Surat district, June 2009-March 2010. *The Journal of the Association of Physicians of India*. 2012;60:15-9.
129. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. *Current medical research and opinion*. 2007;23(12):2961-70.
130. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. *MedGenMed : Medscape general medicine*. 2007;9(4):23.
131. Boehringer, C.. Novel influenza A 2009 - A comparison of intensive care unit vs non-intensive care unit patients. *International Journal of Infectious Diseases*. 2010;14:e93.
132. Brogan TV, Hall M, Sills MR, Fieldston ES, Simon HK, Mundorff MB, Fagbuyi DB, Shah SS. Hospital Readmissions Among Children With H1N1 Influenza Infection. *Hospital pediatrics*. 2014;4(6):348-58.
133. Calatayud L, Kurkela S, Neave PE, Brock A, Perkins S, Zuckerman M, Sudhanva M, Bermingham A, Ellis J, Pebody R, Catchpole M, Heathcock R, Maguire H. Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009: an observational study. *Epidemiology and infection*. 2010;138(2):183-91.
134. Calatayud L, Lackenby A, Reynolds A, McMenamin J, Phin NF, Zambon M, Pebody R. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. *Emerging infectious diseases*. 2011;17(10):1807-15.
135. Campbell CN, Mytton OT, McLean EM, Rutter PD, Pebody RG, Sachedina N, White PJ, Hawkins C, Evans B, Waight PA, Ellis J, Bermingham A, Donaldson LJ, Catchpole M. Hospitalization in two waves of pandemic influenza A(H1N1) in England. *Epidemiology and infection*. 2011;139(10):1560-9.
136. Canadell L, Martín-Loeches I, Díaz E, Trefler S, Grau S, Yebenes JC, Almirall J, Olona M, Sureda F, Blanquer J, Rodriguez A, GETGAG. Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain. *Medicina intensiva*. 2015;39(4):222-33.
137. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, Liang ZA, Liang L, Zhang SJ, Zhang B, Gu L, Lu LH, Wang DY, Wang C, National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. *The New England journal of medicine*. 2009;361(26):2507-17.
138. Carcione D, Giele CM, Goggin LS, Kwan KS, Smith DW, Dowse GK, Mak DB, Effler P. Secondary attack rate of pandemic influenza A(H1N1) 2009 in Western Australian

- households, 29 May-7 August 2009. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2011;16(3).
139. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. *Circulation. Cardiovascular quality and outcomes*. 2009;2(2):108-15.
 140. Centers for Disease Control and Prevention (CDC). 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. *MMWR. Morbidity and mortality weekly report*. 2010;59(11):321-6.
 141. Centers for Disease Control and Prevention (CDC). Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009. *MMWR. Morbidity and mortality weekly report*. 2009;58(19):536-41.
 142. Centers for Disease Control and Prevention (CDC). Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)--United States, April 2009-August 2010. *MMWR. Morbidity and mortality weekly report*. 2011;60(35):1193-6.
 143. Centers for Disease Control and Prevention (CDC). Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents - three states, 2009. *MMWR. Morbidity and mortality weekly report*. 2010;59(3):74-7.
 144. Centers for Disease Control and Prevention (CDC). Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009. *MMWR. Morbidity and mortality weekly report*. 2010;58(51):1436-40.
 145. Chan PK, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasimov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bamgboye E, Swenson A, Toovey S, Dreyer NA. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. *The Journal of infectious diseases*. 2012;206(9):1359-66.
 146. Chawla R, Kansal S, Chauhan M, Jain A, Jibhkate BN. Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): Experiences of a tertiary care center. *Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine*. 2013;17(5):275-82.
 147. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. *Medicine*. 2006;85(5):278-87.
 148. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2007;44(7):964-7.
 149. Chen Y, Qiao H, Zhang CM, Tong M, Shang S. Risk factors for prolonged shedding of 2009 H1N1 influenza virus. *Indian pediatrics*. 2011;48(12):961-3.
 150. Chien YS, Su CP, Tsai HT, Huang AS, Lien CE, Hung MN, Chuang JH, Kuo HS, Chang SC. Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan. *The Journal of infection*. 2010;60(2):168-74.
 151. Chitnis AS, Truelove SA, Druckenmiller JK, Heffernan RT, Davis JP. Epidemiologic and clinical features among patients hospitalized in Wisconsin with 2009 H1N1 influenza A virus

- infections, April to August 2009. *WMJ : official publication of the State Medical Society of Wisconsin*. 2010;109(4):201-8.
152. Choi WI, Yim JJ, Park J, Kim SC, Na MJ, Lee WY, Hong SB, Choi HS, Jang SH, Kim WJ, Jeon K, Kim JH, Choi JC, Lee CH, Kim CH, Kim JY. Clinical characteristics and outcomes of H1N1-associated pneumonia among adults in South Korea. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2011;15(2):270-5, i.
153. Choi, Eun Young, Huh, Jin Won, Lim, Chae-Man, Koh, Younsuck, Kim, Sung-Han, Choi, Sang-Ho, Kim, Won Young, Kim, Won, Kim, Mi-Na, Hong, Sang-Bum. Critically ill patients with pandemic influenza A/H1N1 2009 at a Medical Center in Korea. *Tuberculosis and Respiratory Diseases*. 2011;70(1):28-35.
154. Chowell G, Echevarría-Zuno S, Viboud C, Simonsen L, Miller MA, Fernández-Gárate I, González-Bonilla C, Borja-Aburto VH. Epidemiological characteristics and underlying risk factors for mortality during the autumn 2009 pandemic wave in Mexico. *PLoS one*. 2012;7(7):e41069.
155. Chowell G, Viboud C, Simonsen L, Miller MA, Echevarría-Zuno S, González-León M, Aburto VH. Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico. *BMC infectious diseases*. 2012;12:97.
156. Chudasama RK, Patel UV, Verma PB, Amin CD, Savaria D, Ninama R, Fichadiya N. Clinico-epidemiological features of the hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in Saurashtra region, India (September, 2009 to February, 2010). *Lung India : official organ of Indian Chest Society*. 2011;28(1):11-6.
157. Chudasama RK, Patel UV, Verma PB. Characteristics of Hospitalized Patients with Severe and Non-Severe Pandemic Influenza A (H1N1) in Saurashtra Region, India (Two Waves Analysis). *Journal of family medicine and primary care*. 2013;2(2):182-7.
158. Chudasama RK, Patel UV, Verma PB. Hospitalizations associated with 2009 influenza A (H1N1) and seasonal influenza in Saurashtra region, India. *Journal of infection in developing countries*. 2010;4(12):834-41.
159. Chudasama RK, Verma PB, Amin CD, Gohel B, Savariya D, Ninama R. Correlates of severe disease in patients admitted with 2009 pandemic influenza A (H1N1) infection in Saurashtra region, India. *Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine*. 2010;14(3):113-20.
160. Chudasama, Rajesh K, Patel, Umed V, Verma, Pramod B, Amin, Chikitsa D, Shah, Hitesh M, Banerjee, Anupam, Patel, Ravikant R. Characteristics of fatal cases of pandemic influenza A (H1N1) from September 2009 to January 2010 in Saurashtra Region, India. *Online Journal of Health and Allied Sciences*. 2011;9(4).
161. Cole JA, Loughlin JE, Ajene AN, Rosenberg DM, Cook SE, Walker AM. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. *Clinical therapeutics*. 2002;24(11):1824-39.
162. Colombo C, Battezzati PM, Lucidi V, Magazzù G, Motta V, Alicandro G, Taccetti G, Repetto T. Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. *Thorax*. 2011;66(3):260-1.
163. Cordero E, Pérez-Romero P, Moreno A, Len O, Montejo M, Vidal E, Martín-Dávila P, Fariñas MC, Fernández-Sabé N, Giannella M, Pachón J, Novel influenza A(H1N1) Study Group

- of Spanish Network for Research in Infectious Diseases (REIPI). Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2012;18(1):67-73.
164. Cortes Garcia, Marta, Sierra Moros, Maria Jose, Santa-Olalla Peralta, Patricia, Hernandez-Barrera, Valentin, Jimenez-Garcia, Rodrigo, Pachon, Isabel. Clinical characteristics and outcomes of diabetic patients who were hospitalised with 2009 pandemic influenza A H1N1 infection. *Journal of Infection*. 2012;64(2):218-224.
165. Creanga AA, Johnson TF, Graitcer SB, Hartman LK, Al-Samarrai T, Schwarz AG, Chu SY, Sackoff JE, Jamieson DJ, Fine AD, Shapiro-Mendoza CK, Jones LE, Uyeki TM, Balter S, Bish CL, Finelli L, Honein MA. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. *Obstetrics and gynecology*. 2010;115(4):717-26.
166. Creanga AA, Kamimoto L, Newsome K, D'Mello T, Jamieson DJ, Zotti ME, Arnold KE, Baumbach J, Bennett NM, Farley MM, Gershman K, Kirschke D, Lynfield R, Meek J, Morin C, Reingold A, Ryan P, Schaffner W, Thomas A, Zansky S, Finelli L, Honein MA. Seasonal and 2009 pandemic influenza A (H1N1) virus infection during pregnancy: a population-based study of hospitalized cases. *American journal of obstetrics and gynecology*. 2011;204(6 Suppl 1):S38-45.
167. Cui W, Zhao H, Lu X, Wen Y, Zhou Y, Deng B, Wang Y, Wang W, Kang J, Liu P. Factors associated with death in hospitalized pneumonia patients with 2009 H1N1 influenza in Shenyang, China. *BMC infectious diseases*. 2010;10:145.
168. Custodio, Haidee T, Gayle, Michael O, Bailey, Christine S, Wludyka, Peter S, Rathore, Mobeen H. Comparison of ICU and non-ICU patients infected with the 2009 H1N1 influenza virus in a Florida Children's hospital between April and December 2009. *Eastern Journal of Medicine*. 2011;16(3):188.
169. Da Dalt L, Chillemi C, Cavicchiolo ME, Bressan S, Calistri A, Palù G, Perilongo G. Pandemic influenza A (H1N1v) infection in pediatric population: a multicenter study in a north-east area of Italy. *Italian journal of pediatrics*. 2011;37:24.
170. Dashti-Khavidaki S, Khalili H, Gholamalipour F, Soudbakhsh A, Talasaz AH, Hajabdolbaghi M, Rasoolinejad M, Mokhtari Azad T, Fathi M, Talebian MT, Nasiripour S. Approach to Pandemic 2009 influenza: first report from a main referral hospital for Pandemic H1N1 influenza care in Iran. *Journal of infection in developing countries*. 2010;4(10):629-35.
171. Delgado-Rodríguez M, Castilla J, Godoy P, Martín V, Soldevila N, Alonso J, Astray J, Baricot M, Cantón R, Castro A, González-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Sáez M, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza Working Group. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. *The Journal of antimicrobial chemotherapy*. 2012;67(7):1739-45.
172. Desmoulins C, Michard-Lenoir AP, Naud J, Claudet I, Nouyrigat V, Chéron G. [Clinical features and outcome of 2009 H1N1 influenza in the pediatric setting. Multicenter prospective study in the ED]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 2011;18(5):505-11.
173. Dharan NJ, Gubareva LV, Klimov AI, Fiore AE, Bresee JS, Fry AM. Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A

- (H1N1) infection during the 2007-2008 influenza season in the United States. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(4):621-2.
174. Di Giambenedetto S, Zileri Dal Verme L, Sali M, Farina S, Di Cristo V, Manzara S, De Luca A, Pignataro G, Prospero M, Di Franco A, Gentiloni Silveri N, Delogu G, Cauda R, Fabbiani M, Fadda G. Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2011;30(4):541-9.
175. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, Poblano-Morales M, Baltazar-Torres JA, Bautista E, Martinez A, Martinez MA, Rivero E, Valdez R, Ruiz-Palacios G, Hernández M, Stewart TE, Fowler RA. Critically ill patients with 2009 influenza A(H1N1) in Mexico. *JAMA*. 2009;302(17):1880-7.
176. Dubar G, Azria E, Tesnière A, Dupont H, Le Ray C, Baugnon T, Matheron S, Luton D, Richard JC, Launay O, Tsatsaris V, Goffinet F, Mignon A, French Registry on 2009 A/H1N1v during pregnancy. French experience of 2009 A/H1N1v influenza in pregnant women. *PLoS one*. 2010;5(10).
177. Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. *BJOG : an international journal of obstetrics and gynaecology*. 2014;121(7):901-6.
178. Echenique IA, Chan PA, Chapin KC, Andrea SB, Fava JL, Mermel LA. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. *PLoS one*. 2013;8(4):e60845.
179. Echevarría-Zuno S, Mejía-Arangur JM, Mar-Obeso AJ, Grajales-Muñiz C, Robles-Pérez E, González-León M, Ortega-Alvarez MC, Gonzalez-Bonilla C, Rascón-Pacheco RA, Borja-Aburto VH. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. *Lancet (London, England)*. 2009;374(9707):2072-9.
180. Ellington SR, Hartman LK, Acosta M, Martinez-Romo M, Rubinson L, Jamieson DJ, Louie J. Pandemic 2009 influenza A (H1N1) in 71 critically ill pregnant women in California. *American journal of obstetrics and gynecology*. 2011;204(6 Suppl 1):S21-30.
181. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. *Pharmacoepidemiology and drug safety*. 2004;13(4):227-37.
182. Ergönül Ö, Alan S, Ak Ö, Sargin F, Kantürk A, Gündüz A, Engin D, Öncül O, Balkan II, Ceylan B, Benzonana N, Yazıcı S, Şimşek F, Uzun N, Inan A, Gulhan E, Ciblak M, Midilli K, Ozyurt M, Badur S, Gencer S, Nazlıcan O, Özer S, Özgüneş N, Yıldırım T, Aslan T, Göktaş P, Saltoğlu N, Fincancı M, Dokucu AI, Eraksoy H, Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK), Pandemic Influenza Study Group. Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults. *BMC infectious diseases*. 2014;14:317.
183. Estenssoro E, Ríos FG, Apezteguía C, Reina R, Neira J, Ceraso DH, Orlandi C, Valentini R, Tiribelli N, Brizuela M, Balasini C, Mare S, Domeniconi G, Ilutovich S, Gómez A, Giuliani J, Barrios C, Valdez P, Registry of the Argentinian Society of Intensive Care SATI. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. *American journal of respiratory and critical care medicine*. 2010;182(1):41-8.

184. Fallo AA, Contrini MM, Neyro S, López EL. Case characteristics and use of oseltamivir in children and household contacts. *The Pediatric infectious disease journal*. 2012;31(7):781-3.
185. Fanella ST, Pinto MA, Bridger NA, Bullard JM, Coombs JM, Crockett ME, Olekson KL, Poliquin PG, Van Caesele PG, Embree JE. Pandemic (H1N1) 2009 influenza in hospitalized children in Manitoba: nosocomial transmission and lessons learned from the first wave. *Infection control and hospital epidemiology*. 2011;32(5):435-43.
186. Farias JA, Fernández A, Monteverde E, Vidal N, Arias P, Montes MJ, Rodríguez G, Allasia M, Ratto ME, Jaén R, Meregalli C, Figuepron K, Calvo AR, Siaba A, Albano L, Poterala R, Neira P, Esteban A. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. *Intensive care medicine*. 2010;36(6):1015-22.
187. Figueiró-Filho EA, Oliveira ML, Pompilio MA, Uehara SN, Coelho LR, De Souza BA, Breda I. Obstetric, clinical, and perinatal implications of H1N1 viral infection during pregnancy. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2012;116(3):214-8.
188. Fraaij PL, van der Vries E, Beersma MF, Riezebos-Brilman A, Niesters HG, van der Eijk AA, de Jong MD, Reis Miranda D, Horrevorts AM, Ridwan BU, Wolfhagen MJ, Houmes RJ, van Dissel JT, Fouchier RA, Kroes AC, Koopmans MP, Osterhaus AD, Boucher CA. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. *The Journal of infectious diseases*. 2011;204(5):777-82.
189. France AM, Jackson M, Schrag S, Lynch M, Zimmerman C, Biggerstaff M, Hadler J. Household transmission of 2009 influenza A (H1N1) virus after a school-based outbreak in New York City, April-May 2009. *The Journal of infectious diseases*. 2010;201(7):984-92.
190. Fuhrman C, Bonmarin I, Bitar D, Cardoso T, Duport N, Herida M, Isnard H, Guidet B, Mimoz O, Richard JC, Brun-Buisson C, Brochard L, Mailles A, Paty AC, Saura C, Lévy-Bruhl D. Adult intensive-care patients with 2009 pandemic influenza A(H1N1) infection. *Epidemiology and infection*. 2011;139(8):1202-9.
191. Fuhrman C, Bonmarin I, Paty AC, Duport N, Chiron E, Lucas E, Bitar D, Mailles A, Herida M, Vaux S, Lévy-Bruhl D. Severe hospitalised 2009 pandemic influenza A(H1N1) cases in France, 1 July-15 November 2009. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2010;15(2).
192. Gavalda J, Cabral E, Alonso E, Perez-Romero P, Pérez A, Quintero J, Campins M, Vilalta R, Alonso A, Len O, Navarro M, Nieto J, Jara P, Charco R, Pahissa A, Cordero E. Influenza A H1N1/2009 infection in pediatric solid organ transplant recipients. *Transplant infectious disease : an official journal of the Transplantation Society*. 2012;14(6):584-8.
193. Giannella M, Alonso M, Garcia de Viedma D, Lopez Roa P, Catalán P, Padilla B, Muñoz P, Bouza E. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2011;17(8):1160-5.
194. Gilca R, De Serres G, Boulianne N, Ouhoumane N, Papenburg J, Douville-Fradet M, Fortin É, Dionne M, Boivin G, Skowronski DM. Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. *Influenza and other respiratory viruses*. 2011;5(4):247-55.

195. Goldstein E, Cowling BJ, O'Hagan JJ, Danon L, Fang VJ, Hagy A, Miller JC, Reshef D, Robins J, Biedrzycki P, Lipsitch M. Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. *BMC infectious diseases*. 2010;10:211.
196. González-Vélez AE, Díaz-Agero-Pérez C, Robustillo-Rodela A, Cornejo-Gutiérrez AM, Pita-López MJ, Oliva-Iñiguez L, Monge-Jodra V. [Factors associated to admission to Intensive Care in patients hospitalized due to pandemic Influenza A/H1N1 2009]. *Medicina intensiva*. 2011;35(8):463-9.
197. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. *Expert opinion on pharmacotherapy*. 2008;9(2):151-61.
198. Hagerman A, Posfay-Barbe KM, Duppenhaler A, Heining U, Berger C, PIGS Influenza Study Group. Clinical characteristics and outcomes in children hospitalised with pandemic influenza A/H1N1/09 virus infection – a nationwide survey by the Pediatric Infectious Diseases Group of Switzerland. *Swiss medical weekly*. 2015;145:w14171.
199. Hama R, Jones M, Okushima H, Kitao M, Noda N, Hayashi K, Sakaguchi K. Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza. *The International journal of risk & safety in medicine*. 2011;23(4):201-15.
200. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V, Kaewchana S, Areechokechai D, Levy J, Ungchusak K. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. *PloS one*. 2009;4(6):e6051.
201. Harvala H, Gunson R, Simmonds P, Hardie A, Bennett S, Scott F, Roddie H, McKnight J, Walsh T, Rowney D, Clark A, Bremner J, Aitken C, Templeton K. The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2010;15(14).
202. Hasegawa M, Okada T, Sakata H, Nakayama E, Fuchigami T, Inamo Y, Mugishima H, Tajima T, Iwata S, Morozumi M, Ubukata K, Watanabe H, Takahashi T. Pandemic (H1N1) 2009-associated pneumonia in children, Japan. *Emerging infectious diseases*. 2011;17(2):279-82.
203. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. *JAMA : the journal of the American Medical Association*. 2007;297(13):1435-42.
204. Hernandez JE, Adiga R, Armstrong R, Bazan J, Bonilla H, Bradley J, Dretler R, Ison MG, Mangino JE, Maroushek S, Shetty AK, Wald A, Ziebold C, Elder J, Hollister AS, Sheridan W, eIND Peramivir Investigators. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;52(6):695-706.
205. Hernández-García I, García-Iglesias MA, López-García E, Sáenz-González Mdel C. [Epidemiological characteristics of hospitalized patients with influenza caused by A(H1N1) 2009 virus]. *Gaceta sanitaria*. 2010;24(6):501-2.

206. Hiba V, Chowders M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. *The Journal of antimicrobial chemotherapy*. 2011;66(5):1150-5.
207. Hien ND, Ha NH, Van NT, Ha NT, Lien TT, Thai NQ, Trang VD, Shimbo T, Takahashi Y, Kato Y, Kawana A, Akita S, Kudo K. Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005. *Emerging infectious diseases*. 2009;15(1):19-23.
208. Hien TT, Boni MF, Bryant JE, Ngan TT, Wolbers M, Nguyen TD, Truong NT, Dung NT, Ha do Q, Hien VM, Thanh TT, Nhu le NT, Uyen le TT, Nhien PT, Chinh NT, Chau NV, Farrar J, van Doorn HR. Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis. *PLoS medicine*. 2010;7(5):e1000277.
209. Higuera Iglesias AL, Kudo K, Manabe T, Corcho Berdugo AE, Corrales Baeza A, Alfaro Ramos L, Guevara Gutiérrez R, Manjarrez Zavala ME, Takasaki J, Izumi S, Bautista E, Perez Padilla JR. Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico. *PloS one*. 2011;6(7):e21838.
210. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. *International journal of pediatrics*. 2012;2012:834181.
211. Hirotsu N, Wada K, Oshitani H. Risk factors of household transmission of pandemic (H1N1) 2009 among patients treated with antivirals: a prospective study at a primary clinic in Japan. *PloS one*. 2012;7(2):e31519.
212. Hsann YM, Thang SP, Abdul Salam ZH, Yang Y, Sui-Leong Lim V, Yang KS. Clinical characteristics and outcomes of hospitalized patients with 2009 H1N1 influenza in a large acute care tertiary hospital, Singapore. *American journal of infection control*. 2011;39(8):e49-e51.
213. Huang YC, Li WC, Tsao KC, Huang CG, Chiu CH, Lin TY. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. *The Pediatric infectious disease journal*. 2009;28(7):647-8.
214. Iioka F, Sada R, Maesako Y, Nakamura F, Ohno H. Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation. *International journal of hematology*. 2012;96(3):364-9.
215. Imamura T, Hosoya M, Oonishi N, Sato K, Katayose M, Kawasaki Y, Suzuki H. [The study on efficacy of oseltamivir for influenza A in children]. *Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases*. 2003;77(11):971-6.
216. Jackson ML, France AM, Hancock K, Lu X, Veguilla V, Sun H, Liu F, Hadler J, Harcourt BH, Esposito DH, Zimmerman CM, Katz JM, Fry AM, Schrag SJ. Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave--New York City, April-May 2009. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;53(5):455-62.
217. Jahić R, Ahmetagić S, Porobić-Jahić H, Piljić D, Numanović F. Predictors of the therapeutic response of patients with influenza A (H1N1) 2009 infection. *Medicinski glasnik :*

- official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. 2013;10(2):332-8.
218. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L, 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. *The New England journal of medicine*. 2009;361(20):1935-44.
219. Javadi AA, Ataei B, Khorvash F, Babak A, Rostami M, Mostafavizadeh K, Naeini AE, Meidani M, Salehi H, Avijgan M, Sherkat R, Yazdani MR, Rezaei F. Clinical features of novel 2009 influenza A (H1N1) infection in Isfahan, Iran. *Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences*. 2011;16(12):1550-4.
220. Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F, Bancroft E, Farley S, Ginsberg M, Hernandez LB, Sallenave CS, Radner AB. Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(10):e59-62.
221. Jeon MH, Chung JW, Choi SH, Kim TH, Lee EJ, Choo EJ. Pneumonia risk factors and clinical features of hospitalized patients older than 15 years with pandemic influenza A (H1N1) in South Korea: a multicenter study. *Diagnostic microbiology and infectious disease*. 2011;70(2):230-5.
222. Johnson, Dr Richard, Schweinle, Jo Ellen, Burroughs, Scott. Zanamivir for the Treatment of Clinically Diagnosed Influenza in Clinical Practice. *Clinical Drug Investigation*. 2012;20(5):327-336.
223. Kandeel A, Manoncourt S, Abd el Kareem E, Mohamed Ahmed AN, El-Refai S, Essmat H, Tjaden J, de Mattos CC, Earhart KC, Marfin AA, El-Sayed N. Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006-2009. *Emerging infectious diseases*. 2010;16(7):1101-7.
224. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, Harun S, Soni E, Septiawati C, Setiawati T, Sariwati E, Wandra T. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. *Lancet*. 2008;372(9640):744-9.
225. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2009;49(12):1828-35.
226. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Iwakuni O, Egashira K, Yamaji K, Kashiwagi S. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2012;18(2):180-6.
227. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Kashiwagi S. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. *The Journal of infection*. 2009;59(3):207-12.

228. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kanazawa H, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Nagai T, Horii S, Hirotsu N, Kashiwagi S. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. *The Journal of infection*. 2008;56(1):51-7.
229. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, Kashiwagi S. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2006;43(4):439-44.
230. Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T, Miyachi K, Hirotsu N, Shigematsu T, Kashiwagi S. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2005;40(9):1309-16.
231. Kawai N, Ikematsu H, Kawashima T, Maeda T, Ukai H, Hirotsu N, Iwaki N, Kashiwagi S. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B. *Influenza and other respiratory viruses*. 2013;7(3):448-55.
232. Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, Hirotsu N, Nishimura M, Iwaki N, Kashiwagi S. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2011;17(3):375-81.
233. Kaya S, Yilmaz G, Arslan M, Oztuna F, Ozlu T, Koksali I. Predictive factors for fatality in pandemic influenza A (H1N1) virus infected patients. *Saudi medical journal*. 2012;33(2):146-51.
234. Kedia S, Stroud B, Parsons J, Schreiner T, Curtis DJ, Bagdure D, Brooks-Kayal AR, Glode MP, Dominguez SR. Pediatric neurological complications of 2009 pandemic influenza A (H1N1). *Archives of neurology*. 2011;68(4):455-62.
235. Kendirli T, Demirkol D, Yildizdas D, Anil AB, Asilioğlu N, Karapinar B, Erkek N, Sevketoglu E, Dursun O, Arslanköylü AE, Bayrakçi B, Bosnak M, Köroğlu T, Horoz OO, Citak A, Kesici S, Ates C, Karaböcüoğlu M, Ince E. Critically ill children with pandemic influenza (H1N1) in pediatric intensive care units in Turkey. *Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies*. 2012;13(1):e11-7.
236. Kim SG, Hwang YH, Shin YH, Kim SW, Jung WS, Kim SM, Oh JM, Lee NY, Kim MJ, Cho KS, Park YG, Min SK, Lee CK, Kim JS, Kang C, Lee JY, Huh MK, Kim CH. Occurrence and characterization of oseltamivir-resistant influenza virus in children between 2007-2008 and 2008-2009 seasons. *Korean journal of pediatrics*. 2013;56(4):165-75.
237. Kim WY, Young Suh G, Huh JW, Kim SH, Kim MJ, Kim YS, Kim HR, Ryu YJ, Han MS, Ko YG, Chon GR, Lee KH, Choi SH, Hong SB, Korean Society of Critical Care Medicine H1N1 Collaborative. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. *Antimicrobial agents and chemotherapy*. 2011;55(12):5703-9.

238. Kirakli C, Tatar D, Cimen P, Edipoglu O, Coskun M, Celikten E, Ozsoz A. Survival from severe pandemic H1N1 in urban and rural Turkey: a case series. *Respiratory care*. 2011;56(6):790-5.
239. Koegelenberg CF, Iruzen EM, Cooper R, Diacon AH, Taljaard JJ, Mowlana A, von Groote-Bidlingmaier F, Bolliger CT. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. *QJM : monthly journal of the Association of Physicians*. 2010;103(5):319-25.
240. Komiya N, Gu Y, Kamiya H, Yahata Y, Matsui T, Yasui Y, Okabe N. Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2009;14(29).
241. Komiya N, Gu Y, Kamiya H, Yahata Y, Yasui Y, Taniguchi K, Okabe N. Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009. *The Journal of infection*. 2010;61(4):284-8.
242. Koseki N, Kaiho M, Kikuta H, Oba K, Togashi T, Ariga T, Ishiguro N. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. *Influenza and other respiratory viruses*. 2014;8(2):151-8.
243. Kudo K, Takasaki J, Manabe T, Uryu H, Yamada R, Kuroda E, Kobayashi N, Matsushita T. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. *PloS one*. 2012;7(2):e32280.
244. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, Danziger-Isakov L, Stosor V, Estabrook M, Gantt S, Marr KA, Martin S, Silveira FP, Razonable RR, Allen UD, Levi ME, Lyon GM, Bell LE, Huprikar S, Patel G, Gregg KS, Pursell K, Helmersen D, Julian KG, Shiley K, Bono B, Dharnidharka VR, Alavi G, Kalpoe JS, Shoham S, Reid GE, Humar A, American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. *The Lancet infectious diseases*. 2010;10(8):521-6.
245. Kuszniierz G, Uboldi A, Sosa G, Torales S, Colombo J, Moyano C, Escobar H, Lejona S, Anchart E, Gómez A, Imaz S. Clinical features of the hospitalized patients with 2009 pandemic influenza A (H1N1) in Santa Fe, Argentina. *Influenza and other respiratory viruses*. 2013;7(3):410-7.
246. Kute V, Goplani KR, Godara SM, Shah PR, Vanikar AV, Trivedii HL. Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppressive drug interaction. *The Journal of the Association of Physicians of India*. 2011;59:49-51.
247. Kwan-Gett TS, Baer A, Duchin JS. Spring 2009 H1N1 influenza outbreak in King County, Washington. *Disaster medicine and public health preparedness*. 2009;3 Suppl 2:S109-16.
248. L'Huillier AG, Ing Lorenzini K, Crisinel PA, Rebsamen MC, Fluss J, Korff CM, Barbe RP, Siegrist CA, Dayer P, Posfay-Barbe KM, Desmeules JA, H1N1 Pediatric Epidemiology Study Group of Geneva. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemic. *Pharmacogenomics*. 2011;12(10):1493-501.

249. Lackenby A, Elliot AJ, Powers C, Andrews N, Ellis J, Bermingham A, Thompson C, Galiano M, Large S, Durnall H, Fleming D, Smith G, Zambon M. Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort. *The Journal of antimicrobial chemotherapy*. 2013;68(10):2324-31.
250. Launes C, García-García JJ, Jordán I, Martínez-Planas A, Selva L, Muñoz-Almagro C. 2009 Influenza A H1N1 infections: delays in starting treatment with oseltamivir were associated with a more severe disease. *The Pediatric infectious disease journal*. 2011;30(7):622-5.
251. Lee CS, Lee JH. Dynamics of clinical symptoms in patients with pandemic influenza A (H1N1). *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2010;16(4):389-90.
252. Lee CY, Chuang YF, Huang WY, Cheng SH, Pei JS. Epidemiology, clinical features, treatment, and outcomes of cases of influenza A infection during the 2009 influenza pandemic in northern Taiwan. *Pediatrics and neonatology*. 2012;53(4):257-63.
253. Lee EH, Wu C, Lee EU, Stoute A, Hanson H, Cook HA, Nivin B, Fine AD, Kerker BD, Harper SA, Layton MC, Balter S. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(11):1498-504.
254. Lee IK, Liu JW, Wang L, Yang KD, Li CC, Eng HL. 2009 pandemic influenza A (H1N1): clinical and laboratory characteristics in pediatric and adult patients and in patients with pulmonary involvement. *Influenza and other respiratory viruses*. 2012;6(6):e152-61.
255. Lee JS, Park SY, Kim JS, You JY, Ju YS, Eom JS. The clinical effectiveness of oseltamivir in mild cases of pandemic influenza A H1N1 2009 infection. *Scandinavian journal of infectious diseases*. 2012;44(8):595-9.
256. Lee N, Chan PK, Choi KW, Lui G, Wong B, Cockram CS, Hui DS, Lai R, Tang JW, Sung JJ. Factors associated with early hospital discharge of adult influenza patients. *Antiviral therapy*. 2007;12(4):501-8.
257. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, Lui GC, Wong BC, Wong RY, Lam WY, Chu IM, Lai RW, Cockram CS, Sung JJ. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. *The Journal of infectious diseases*. 2009;200(4):492-500.
258. Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RY, Lee EL, Yeung AC, Ngai KL, Chan MC, Lai RW, Yu AW, Hui DS. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?. *The Journal of infectious diseases*. 2011;203(12):1739-47.
259. Lee N, Choi KW, Chan PK, Hui DS, Lui GC, Wong BC, Wong RY, Sin WY, Hui WM, Ngai KL, Cockram CS, Lai RW, Sung JJ. Outcomes of adults hospitalised with severe influenza. *Thorax*. 2010;65(6):510-5.
260. Lee VJ, Yap J, Cook AR, Chen MI, Tay JK, Tan BH, Loh JP, Chew SW, Koh WH, Lin R, Cui L, Lee CW, Sung WK, Wong CW, Hibberd ML, Kang WL, Seet B, Tambyah PA. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. *The New England journal of medicine*. 2010;362(23):2166-74.
261. Leick-Courtois C, Haÿs S, Basson E, Mory-Thomas N, Boibieux A, Picaud JC. Oseltamivir treatment for influenza does not increase digestive intolerance in preterm infants. *Acta paediatrica (Oslo, Norway : 1992)*. 2014;103(3):e136-7.

262. Lenzi L, Grochocki MHC, Silva LR et al. Evaluation of the effectiveness of oseltamivir for the treatment of 2009 pandemic influenza A (H1N1). *International Journal of Tropical Disease and Health*. 2012;2:132-144.
263. Lenzi L, Wiens A, Pontarolo R. The characteristics, clinical manifestations and outcomes of pandemic influenza A (H1N1) 2009 in the elderly. *Revista da Sociedade Brasileira de Medicina Tropical*. 2013;46(2):135-40.
264. Lenzi L, de Mello AM, da Silva LR et al. Clinical manifestations, outcomes and prognostic factors of the 2009 pandemic influenza A (H1N1) in children. *Revista Paulista de Pediatria*. 2012;30:346-352.
265. Lera E, Wörner NT, Sancosmed M, Fàbregas A, Casquero A, Melendo S, Miserachs M, Tórtola T, Borrego A, Campins M, Moraga F, Figueras C, Cebrián R. Clinical and epidemiological characteristics of patients with influenza A (H1N1) 2009 attended to at the emergency room of a children's hospital. *European journal of pediatrics*. 2011;170(3):371-8.
266. Leung YH, Li MP, Chuang SK. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. *Epidemiology and infection*. 2011;139(1):41-4.
267. Leung YH, Lim WL, Wong MH, Chuang SK. Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus. *Epidemiology and infection*. 2012;140(5):814-7.
268. Leung YH, To MK, Lam TS, Yau SW, Leung OS, Chuang SK. Epidemiology of human influenza A(H7N9) infection in Hong Kong. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*. 2017;50(2):183-188.
269. Li IW, Hung IF, To KK, Chan KH, Wong SS, Chan JF, Cheng VC, Tsang OT, Lai ST, Lau YL, Yuen KY. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. *Chest*. 2010;137(4):759-68.
270. Libster R, Bugna J, Coviello S, Hijano DR, Dunaiewsky M, Reynoso N, Cavalieri ML, Guglielmo MC, Areso MS, Gilligan T, Santucho F, Cabral G, Gregorio GL, Moreno R, Lutz MI, Panigasi AL, Saligari L, Caballero MT, Egües Almeida RM, Gutierrez Meyer ME, Neder MD, Davenport MC, Del Valle MP, Santidrian VS, Mosca G, Garcia Domínguez M, Alvarez L, Landa P, Pota A, Boloñati N, Dalamon R, Sanchez Mercol VI, Espinoza M, Peuchot JC, Karolinski A, Bruno M, Borsa A, Ferrero F, Bonina A, Ramonet M, Albano LC, Luedicke N, Alterman E, Savy V, Baumeister E, Chappell JD, Edwards KM, Melendi GA, Polack FP. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. *The New England journal of medicine*. 2010;362(1):45-55.
271. Liem NT, Tung CV, Hien ND, Hien TT, Chau NQ, Long HT, Hien NT, Mai le Q, Taylor WR, Wertheim H, Farrar J, Khang DD, Horby P. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2009;48(12):1639-46.
272. Ling LM, Chow AL, Lye DC, Tan AS, Krishnan P, Cui L, Win NN, Chan M, Lim PL, Lee CC, Leo YS. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(7):963-9.
273. Lisena F, Bordi L, Carletti F, Castilletti C, Ferraro F, Lalle E, Lanini S, Ruscitti LE, Fusco FM. Influenza A (H1N1) in Rome, Italy in family: three case reports. *Cases journal*. 2009;2:9123.

274. Louie JK, Acosta M, Jamieson DJ, Honein MA, California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. *The New England journal of medicine*. 2010;362(1):27-35.
275. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, Matyas BT, California Pandemic (H1N1) Working Group. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;52(3):301-12.
276. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, Samuel MC, Rosenberg J, Talarico J, Hatch D, California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. *JAMA*. 2009;302(17):1896-902.
277. Louie JK, Gavali S, Acosta M, Samuel MC, Winter K, Jean C, Glaser CA, Matyas BT, Schechter R, California Pandemic (H1N1) Working Group. Children hospitalized with 2009 novel influenza A(H1N1) in California. *Archives of pediatrics & adolescent medicine*. 2010;164(11):1023-31.
278. Louie JK, Jamieson DJ, Rasmussen SA. 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California. *American journal of obstetrics and gynecology*. 2011;204(2):144.e1-6.
279. Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, Guevara H, Uyeki TM. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2012;55(9):1198-204.
280. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. *PloS one*. 2012;7(6):e40261.
281. Low CY, Kee T, Chan KP, Oon LL, Tan CK, Tee NW, Tan BH. Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore. *Transplantation*. 2010;90(9):1016-21.
282. López-Aldeguer J, Iribarren JA, Valencia E, Barquilla E, Knobel H, Santos J, Lozano F, GESIDA 6409 Study Group. Outcomes in HIV-infected patients admitted due to pandemic influenza. *Enfermedades infecciosas y microbiología clinica*. 2012;30(10):608-12.
283. Lückner LM, Kherad O, Iten A, Wagner N, Descombes M, Camus V, Kaiser L, Louis-Simonet M. Clinical features and outcome of hospitalised adults and children with the 2009 influenza A H1N1 infection at Geneva's University Hospital. *Swiss medical weekly*. 2011;141:w13177.
284. Machado CM, Boas LS, Mendes AV, Santos MF, da Rocha IF, Sturaro D, Dulley FL, Pannuti CS. Low mortality rates related to respiratory virus infections after bone marrow transplantation. *Bone marrow transplantation*. 2003;31(8):695-700.
285. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. *Cardiology*. 2009;113(2):98-107.
286. Mady A, Ramadan OS, Yousef A, Mandourah Y, Amr AA, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. *Journal of infection and public health*. 2012;5(1):52-6.
287. Mady, A., Ramadan, O.S., Yousef, A., Mandourah, Y., Amr, A.A., Kherallah, M.. Clinical experience with severe 2009 H1N1 influenza in intensive care unit At King Saud Medical Complex, Saudi Arabia. *Journal of Critical Care*. 2010;25(4):e14-e15.

288. Maltezou HC, Drakoulis N, Siahaniidou T, Karalis V, Zervaki E, Dotsikas Y, Loukas YL, Theodoridou M. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1. *The Pediatric infectious disease journal*. 2012;31(5):527-9.
289. Maraví-Poma E, Martín-Loeches I, Regidor E, Laplaza C, Cambra K, Aldunate S, Guerrero JE, Loza-Vazquez A, Arnau E, Almirall J, Lorente L, Arenzana A, Magret M, Reig Valero R, Marquez E, Gonzalez N, Bermejo-Martin JF, Rello J, Grupo Español de Trabajo de Gripe Grave A (SEMICYUC). Severe 2009 A/H1N1v influenza in pregnant women in Spain. *Critical care medicine*. 2011;39(5):945-51.
290. Marra F, Chong M, Henry B, Patrick DM, Kendall P. Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. *The Journal of antimicrobial chemotherapy*. 2014;69(5):1397-406.
291. Martín-Loeches I, Díaz E, Vidaur L, Torres A, Laborda C, Granada R, Bonastre J, Martín M, Insausti J, Arenzana A, Guerrero JE, Navarrete I, Bermejo-Martin J, Suarez D, Rodriguez A, H1N1 SEMICYUC/REIPI/CIBERES Working group. Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. *Critical care (London, England)*. 2011;15(6):R286.
292. Matsuzaki Y, Mizuta K, Aoki Y, Suto A, Abiko C, Sanjoh K, Sugawara K, Takashita E, Itagaki T, Katsushima Y, Ujike M, Obuchi M, Odagiri T, Tashiro M. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. *Virology journal*. 2010;7:53.
293. McGeer A, Green K, Drews S, Davis I, Downey J, Katz K. et al. Epidemiology of influenza illness requiring intensive care unit admission in Toronto, Canada. *Clin Microbiol Infect*. 2009;15:S26.
294. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, Low DE, Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2007;45(12):1568-75.
295. McLean E, Pebody RG, Campbell C, Chamberland M, Hawkins C, Nguyen-Van-Tam JS, Oliver I, Smith GE, Ihekweazu C, Bracebridge S, Maguire H, Harris R, Kafatos G, White PJ, Wynne-Evans E, Green J, Myers R, Underwood A, Dallman T, Wreghitt T, Zambon M, Ellis J, Phin N, Smyth B, McMenamin J, Watson JM. Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiology and infection*. 2010;138(11):1531-41.
296. Meschi S, Selleri M, Lalle E, Bordi L, Valli MB, Ferraro F, Ippolito G, Petrosillo N, Lauria FN, Capobianchi MR. Duration of viral shedding in hospitalized patients infected with pandemic H1N1. *BMC infectious diseases*. 2011;11:140.
297. Mickienė A, Daniusevičiūtė L, Vanagaitė N, Vėlyvytė D, Blauzdžiūnienė O, Nadišauskienė R, Macas A, Sakalauskas R, Pilvinis V, Nedzelskienė I, Jodžiūnienė L. Hospitalized adult patients with 2009 pandemic influenza A (H1N1) in Kaunas, Lithuania. *Medicina (Kaunas, Lithuania)*. 2011;47(1):11-8.
298. Minnema BJ, Husain S, Mazzulli T, Hosseini-Mogaddam SM, Patel M, Brandwein J, Reece D, Lipton JH, Rotstein C. Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study. *Leukemia & lymphoma*. 2013;54(6):1250-5.

299. Miranda-Choque E, Ramírez C, Candela-Herrera J, Díaz J, Fernández A, Kolevic L, Segura ER, Farfán-Ramos S. [Children hospitalized with influenza pneumonia AH1N1/2009 pandemic in the INSN]. *Revista peruana de medicina experimental y salud publica*. 2011;28(4):610-6.
300. Moral L, Marco N, Toral T, Fuentes MJ, Fuentes L, Lillo L. Burden of severe 2009 pandemic influenza A (H1N1) infection in children in Southeast Spain. *Enfermedades infecciosas y microbiología clínica*. 2011;29(7):497-501.
301. Morgan OW, Parks S, Shim T, Blevins PA, Lucas PM, Sanchez R, Walea N, Loustalot F, Duffy MR, Shim MJ, Guerra S, Guerra F, Mills G, Verani J, Alsip B, Lindstrom S, Shu B, Emery S, Cohen AL, Menon M, Fry AM, Dawood F, Fonseca VP, Olsen SJ. Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April-May 2009. *Emerging infectious diseases*. 2010;16(4):631-7.
302. Muhammad Ismail HI, Tan KK, Lee YL, Pau WS, Razali KA, Mohamed T, Adnan T, Subramaniam P, Hanif J. Characteristics of children hospitalized for pandemic (H1N1) 2009, Malaysia. *Emerging infectious diseases*. 2011;17(4):708-10.
303. Na S, Chong YP, Kim MN, Kim WY, Kim W, Hong SB, Lim CM, Koh Y, Kwon JW, Hong SJ, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. *Journal of medical virology*. 2011;83(1):5-9.
304. Nakai A, Minakami H, Unno N, Saito S, Morikawa M, Yoshimura Y, Terao T. Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009--low mortality rate may be due to early antiviral use. *The Journal of infection*. 2011;62(3):232-3.
305. Nermin KG, Remzi I, Zeynep A, Ilker C, Meltem OT, Guven O, Ferda K, Halis A. A retrospective evaluation of critically ill patients infected with H1N1 influenza A virus in Bursa, Turkey, during the 2009-2010 pandemic. *African health sciences*. 2015;15(2):352-9.
306. Ng S, Cowling BJ, Fang VJ, Chan KH, Ip DK, Cheng CK, Uyeki TM, Houck PM, Malik Peiris JS, Leung GM. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(5):707-14.
307. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Nicholson KG, Influenza Clinical Information Network (FLU-CIN). Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). *Thorax*. 2010;65(7):645-51.
308. Nishiura H, Oshitani H. Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment. *The Journal of international medical research*. 2011;39(2):619-28.
309. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. *Current medical research and opinion*. 2005;21(5):761-8.
310. O'Riordan S, Barton M, Yau Y, Read SE, Allen U, Tran D. Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2010;182(1):39-44.

311. Odaira F, Takahashi H, Toyokawa T, Tsuchihashi Y, Kodama T, Yahata Y, Sunagawa T, Taniguchi K, Okabe N. Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A(H1N1)v outbreak in Kobe, Japan, May-June 2009. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2009;14(35).
312. Oh WS, Lee SJ, Lee CS, Hur JA, Hur AC, Park YS, Heo ST, Bae IG, Park SW, Kim ES, Kim HB, Song KH, Lee KS, Lee SR, Yeom JS, Lee SJ, Kim BN, Kwak YG, Lee JH, Kim YK, Kim HY, Kim NJ, Oh MD. A prediction rule to identify severe cases among adult patients hospitalized with pandemic influenza A (H1N1) 2009. *Journal of Korean medical science*. 2011;26(4):499-506.
313. Oner AF, Dogan N, Gasimov V, Adisasmito W, Coker R, Chan PK, Lee N, Tsang O, Hanshaoworakul W, Zaman M, Bamgboye E, Swenson A, Toovey S, Dreyer NA. H5N1 avian influenza in children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2012;55(1):26-32.
314. Ormsby CE, de la Rosa-Zamboni D, Vázquez-Pérez J, Ablanedo-Terrazas Y, Vega-Barrientos R, Gómez-Palacio M, Murakami-Ogasawara A, Ibarra-Ávalos JA, Romero-Rodríguez D, Avila-Ríos S, Reyes-Terán G. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. *AIDS (London, England)*. 2011;25(4):435-9.
315. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. *Clinical therapeutics*. 2007;29(10):2246-55.
316. Pannaraj PS, Tam B, Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. *Journal of perinatology : official journal of the California Perinatal Association*. 2011;31(7):487-93.
317. Paño-Pardo JR, Rodríguez-Baño J, Martínez-Sánchez N, Viasus D, Fariñas MC, Leyes M, López-Medrano F, Pachón J, Torre-Cisneros J, Oteo JA, Pumarola T, García-Gasalla M, Ortega L, Segura F, Carratalá J, Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Prognosis of 2009 A(H1N1) influenza in hospitalized pregnant women in a context of early diagnosis and antiviral therapy. *Antiviral therapy*. 2012;17(4):719-28.
318. Pebody RG, Harris R, Kafatos G, Chamberland M, Campbell C, Nguyen-Van-Tam JS, McLean E, Andrews N, White PJ, Wynne-Evans E, Green J, Ellis J, Wreghitt T, Bracebridge S, Ihekweazu C, Oliver I, Smith G, Hawkins C, Salmon R, Smyth B, McMenamin J, Zambon M, Phin N, Watson JM. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. *Emerging infectious diseases*. 2011;17(6):990-9.
319. Peralta, P Santa-Olalla, Cortes-Garcia, M, Vicente-Herrero, M, Castrillo-Villamandos, C, Arias-Bohigas, P, Pachon-del Amo, I, Sierra-Moros, MJ. Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April–December 2009. *Eurosurveillance*. 2010;15(38):19667.
320. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA, INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. *The New England journal of medicine*. 2009;361(7):680-9.

321. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. *Medscape journal of medicine*. 2008;10(6):131.
322. Peters PJ, Skarbinski J, Louie JK, Jain S, New York City Department of Health Swine Flu Investigation Team, Roland M, Jani SG, Finelli L, Brooks JT. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1)--United States, spring and summer 2009. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;52 Suppl 1:S183-8.
323. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. *Pediatrics*. 2009;124(1):170-8.
324. Ploin D, Chidiac C, Carrat F, Cohen B, Javouhey E, Mayaud C, Desenclos JC, Lina B, Leport C, Fluco study group. Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections--the Fluco French cohort. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2013;58(1):114-9.
325. Poepl W, Hell M, Herkner H, Stoiser B, Fritsche G, Schurz-Bamieh N, Poepl G, Gatringer R, Jones N, Maass M, Egle A, Burgmann H. Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. *Infection*. 2011;39(4):341-52.
326. Pop-Vicas A, Chahin A, Hagau D, Chapin K. Risk factors for prolonged H1N1 influenza among hospitalized patients. *American journal of infection control*. 2013;41(12):1284-6.
327. Qiao, Chong, Zhao, Jiao, Mao, M. Effect of early antiviral treatment on perinatal prognosis of the pregnant women with severe H1N1 influenza virus infection. *Maternal and Child Health Care of China*. 2011;26(10):1566-1569.
328. Querci M, Stryjewski ME, Herrera F, Temporiti E, Alcalá W, Chavez N, Figueras L, Barberis F, Echavarría M, Videla C, Martínez A, Carballal G, Bonvehí P. Healthcare personnel infected with novel influenza A H1N1 virus in university hospitals in Buenos Aires, Argentina. *Scandinavian journal of infectious diseases*. 2011;43(1):70-4.
329. Rahamat-Langendoen JC, Tutuhaturunewa ED, Schölvinck EH, Hak E, Koopmans M, Niesters HG, Riezebos-Brilman A. Influenza in the immediate post-pandemic era: a comparison with seasonal and pandemic influenza in hospitalized patients. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2012;54(2):135-40.
330. Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, Smoot E, Rice TW, Loftis LL, Helfaer M, Doctor A, Paden M, Flori H, Babbitt C, Graciano AL, Gedeit R, Sanders RC, Giuliano JS, Zimmerman J, Uyeki TM, Pediatric Acute Lung Injury and Sepsis Investigator's Network and the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Critically ill children during the 2009-2010 influenza pandemic in the United States. *Pediatrics*. 2011;128(6):e1450-8.
331. Redlberger-Fritz M, Hirk S, Buchinger D, Haberl R, Hell M, Perkmann-Nagele N, Kundi M, Popow-Kraupp T. Distinct differences in clinical manifestation and viral laboratory parameters between children and adults with influenza A(H1N1)pdm09 infection--a retrospective comparative analysis. *Journal of medical virology*. 2014;86(6):1048-55.
332. Reid G, Huprikar S, Patel G, Razonable RR, Mossad S, Levi M, Gregg K, Shoham S, Humar A, Adams W, Kumar D. A multicenter evaluation of pandemic influenza A/H1N1 in

- hematopoietic stem cell transplant recipients. *Transplant infectious disease : an official journal of the Transplantation Society*. 2013;15(5):487-92.
333. Rello J, Rodríguez A, Ibañez P, Socías L, Cebrian J, Marques A, Guerrero J, Ruiz-Santana S, Marquez E, Del Nogal-Saez F, Alvarez-Lerma F, Martínez S, Ferrer M, Avellanas M, Granada R, Maraví-Poma E, Albert P, Sierra R, Vidaur L, Ortiz P, Prieto del Portillo I, Galván B, León-Gil C, H1N1 SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. *Critical care (London, England)*. 2009;13(5):R148.
334. Reuss A, Dehnert M, Buda S, Haas W. Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany. *Influenza and other respiratory viruses*. 2013;7(6):1427-32.
335. Rhim JW, Go EJ, Lee KY, Youn YS, Kim MS, Park SH, Kim JC, Kang JH. Pandemic 2009 H1N1 virus infection in children and adults: A cohort study at a single hospital throughout the epidemic. *International archives of medicine*. 2012;5(1):13.
336. Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC. Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. *BMC infectious diseases*. 2011;11:225.
337. Ribeiro AF, Pellini AC, Kitagawa BY, Marques D, Madalosso G, de Cassia Nogueira Figueira G, Fred J, Albernaz RK, Carvalhanas TR, Zanetta DM. Risk factors for death from Influenza A(H1N1)pdm09, State of São Paulo, Brazil, 2009. *PloS one*. 2015;10(3):e0118772.
338. Riquelme R, Jiménez P, Videla AJ, Lopez H, Chalmers J, Singanayagam A, Riquelme M, Peyrani P, Wiemken T, Arbo G, Benchetrit G, Rioseco ML, Ayesu K, Klotchko A, Marzoratti L, Raya M, Figueroa S, Saavedra F, Pryluka D, Inzunza C, Torres A, Alvare P, Fernandez P, Barros M, Gomez Y, Contreras C, Rello J, Bordon J, Feldman C, Arnold F, Nakamatsu R, Riquelme J, Blasi F, Aliberti S, Cosentini R, Lopardo G, Gnoni M, Welte T, Saad M, Guardiola J, Ramirez J. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2011;15(4):542-6.
339. Riquelme R, Riquelme M, Rioseco ML, Inzunza C, Gomez Y, Contreras C, Riquelme J, Peyrani P, Wiemken T, Ramirez J. Characteristics of hospitalised patients with 2009 H1N1 influenza in Chile. *The European respiratory journal*. 2010;36(4):864-9.
340. Rodriguez A, Zaragoza R, Daz E, Daz JJ, Marques A, Figueira JC. et al. Early oseltamivir treatment was associated with improved outcomes in 2009 pandemic influenza A (H1N1)v in Spain. *Intensive Care Med*. 2010;36:S136.
341. Rodríguez A, Díaz E, Martín-Loeches I, Sandiumenge A, Canadell L, Díaz JJ, Figueira JC, Marques A, Alvarez-Lerma F, Vallés J, Baladín B, García-López F, Suberviola B, Zaragoza R, Trefler S, Bonastre J, Blanquer J, Rello J, H1N1 SEMICYUC Working Group. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. *The Journal of antimicrobial chemotherapy*. 2011;66(5):1140-9.
342. Ryoo SM, Kim WY, Sohn CH, Seo DW, Oh BJ, Lee JH, Lee YS, Lim KS. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. *Influenza and other respiratory viruses*. 2013;7(5):833-7.
343. Saito R, Sato I, Suzuki Y, Baranovich T, Matsuda R, Ishitani N, Dapat C, Dapat IC, Zaraket H, Oguma T, Suzuki H. Reduced effectiveness of oseltamivir in children infected with

- oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. *The Pediatric infectious disease journal*. 2010;29(10):898-904.
344. Samra T, Pawar M. Health care personnel and risk of H1N1-chemoprophylaxis with oseltamivir. *Indian journal of pharmacology*. 2012;44(6):754-8.
345. Santa-Olalla Peralta P, Cortes García M, Limia Sánchez A, Andrés Prado J, Pachón Del Amo I, Sierra Moros MJ, Subcomité de Vigilancia Epidemiológica del Plan Nacional de Preparación y Respuesta ante una Pandemia de Gripe. [Critically ill patients with 2009 pandemic influenza A (H1N1) infection in Spain: factors associated with death, April 2009-January 2010]. *Revista española de salud pública*. 2010;84(5):547-67.
346. Sato M, Saito R, Sato I, Tanabe N, Shobugawa Y, Sasaki A, Li D, Suzuki Y, Sato M, Sakai T, Oguma T, Tsukada H, Gejyo F, Suzuki H. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. *The Tohoku journal of experimental medicine*. 2008;214(2):113-20.
347. Schellongowski P, Ullrich R, Hieber C, Hetz H, Losert H, Hermann M, Hermann A, Gatringer KB, Siersch V, Rabitsch W, Fuhrmann V, Bojic A, Robak O, Sperr WR, Laczika K, Locker GJ, Staudinger T. A surge of flu-associated adult respiratory distress syndrome in an Austrian tertiary care hospital during the 2009/2010 Influenza A H1N1v pandemic. *Wiener klinische Wochenschrift*. 2011;123(7-8):209-14.
348. Scotta MC, Mattiello R, Marostica PJ, Jones MH, Martins LG, Fischer GB. Risk factors for need of mechanical ventilation in children with influenza A(H1N1)pdm09. *Jornal de pediatria*. 2013;89(5):444-9.
349. Shah DP, El Taoum KK, Shah JN, Vigil KJ, Adachi JA, Granwehr BP, Tarrand JJ, Raad II, Chemaly RF. Characteristics and outcomes of pandemic 2009/H1N1 versus seasonal influenza in children with cancer. *The Pediatric infectious disease journal*. 2012;31(4):373-8.
350. Shen Y, Lu H. Pandemic (H1N1) 2009, Shanghai, China. *Emerging infectious diseases*. 2010;16(6):1011-3.
351. Shi L, Loveless M, Spagnuolo P, Zhang M, Liu S, Liu J, Xu Y, Chen E, Han J. Antiviral treatment of influenza in children: a retrospective cohort study. *Advances in therapy*. 2014;31(7):735-50.
352. Shinde V, Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Kaewchana S, Areechokechai D, Ungchusak K, Fry AM. A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006. *PloS one*. 2011;6(4):e14809.
353. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2012;18(6):858-64.
354. Silagy, Prof C., Watts, R.. Zanamivir, a New Targeted Therapy in the Treatment of Influenza. *Clinical Drug Investigation*. 2012;19(2):111-121.
355. Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, Louie J, Doyle TJ, Crockett M, Lynfield R, Moore Z, Wiedeman C, Anand M, Tabony L, Nielsen CF, Waller K, Page S, Thompson JM, Avery C, Springs CB, Jones T, Williams JL, Newsome K, Finelli L, Jamieson DJ, Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009

- influenza A(H1N1) virus illness among pregnant women in the United States. *JAMA : the journal of the American Medical Association*. 2010;303(15):1517-25.
356. Skarbinski J, Jain S, Bramley A, Lee EJ, Huang J, Kirschke D, Stone A, Wedlake T, Richards SM, Page S, Ragan P, Bullion L, Neises D, Williams RM, Petruccelli BP, Vandermeer M, Lofy KH, Gindler J, Finelli L, 2009 Pandemic Influenza A H1N1 Virus Fall Hospitalizations Investigation Team. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;52 Suppl 1:S50-9.
357. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. *International journal of clinical practice*. 2009;63(4):596-605.
358. Sopirala MM, Haas DM, Ali NA, Mangino JE, Pan X, Turner AN. Effect of fever on hospital presentation, diagnosis, and treatment in patients with H1N1/09 influenza. *Journal of hospital medicine*. 2013;8(1):20-4.
359. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. *BMJ (Clinical research ed.)*. 2013;346:f3039.
360. Souza TM, Salluh JI, Bozza FA, Mesquita M, Soares M, Motta FC, Pitrowsky MT, de Lourdes Oliveira M, Mishin VP, Gubareva LV, Whitney A, Rocco SA, Gonçalves VM, Marques VP, Velasco E, Siqueira MM. H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis. *PloS one*. 2010;5(11):e14158.
361. Stein M, Tasher D, Glikman D, Shachor-Meyouhas Y, Barkai G, Yochai AB, Leibovitz E, Hausman-Kedem M, Hess A, Megged O, Kassis I, Gresario G, Somekh E. Hospitalization of children with influenza A(H1N1) virus in Israel during the 2009 outbreak in Israel: a multicenter survey. *Archives of pediatrics & adolescent medicine*. 2010;164(11):1015-22.
362. Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, Bermingham A, Nicholson K, Zambon M. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2009;48(4):389-96.
363. Subramony H, Lai FY, Ang LW, Cutter JL, Lim PL, James L. An epidemiological study of 1348 cases of pandemic H1N1 influenza admitted to Singapore Hospitals from July to September 2009. *Annals of the Academy of Medicine, Singapore*. 2010;39(4):283-8.
364. Suess T, Buchholz U, Dupke S, Grunow R, an der Heiden M, Heider A, Biere B, Schweiger B, Haas W, Krause G, Robert Koch Institute Shedding Investigation Group. Shedding and transmission of novel influenza virus A/H1N1 infection in households--Germany, 2009. *American journal of epidemiology*. 2010;171(11):1157-64.
365. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, Kawakami C, Kiso M, Ito M, Hatakeyama S, Kawaoka Y. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2007;44(2):197-202.
366. Sugaya N, Sakai-Tagawa Y, Bamba M, Yasuhara R, Yamazaki M, Kawakami C, Yamaguchi Y, Ide Y, Ichikawa M, Mitamura K, Kawaoka Y. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. *Antiviral therapy*. 2015;20(1):49-55.

367. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2008;47(3):339-45.
368. Tabarsi P, Moradi A, Marjani M, Baghaei P, Hashemian SM, Nadji SA, Fakharian A, Mansouri D, Masjedi M, Velayati A. Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. *Annals of thoracic medicine*. 2011;6(2):91-5.
369. Takemoto Y, Asai T, Ikezoe I, Yano T, Ichikawa M, Miyagawa S, Matsumoto J. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. *Chemotherapy*. 2013;59(5):373-8.
370. Takeuchi M, Yasunaga H, Horiguchi H, Matsuda S. Clinical features of infants hospitalized for 2009 pandemic influenza A (H1N1) in Japan: analysis using a national hospital discharge database. *The Pediatric infectious disease journal*. 2012;31(4):368-72.
371. Tasar MA, Dallar Y, Soyer OU et al. Risk factors and prognosis in children hospitalized due to pandemic H1N1 influenza A virus infection in Ankara, Turkey. *Turkish Journal of Medical Sciences*. 2012;42(3):433-440.
372. Teh B, Olsen K, Black J, Cheng AC, Aboltins C, Bull K, Johnson PD, Grayson ML, Torresi J. Impact of swine influenza and quarantine measures on patients and households during the H1N1/09 pandemic. *Scandinavian journal of infectious diseases*. 2012;44(4):289-96.
373. Thompson DL, Jungk J, Hancock E, Smelser C, Landen M, Nichols M, Selvage D, Baumbach J, Sewell M. Risk factors for 2009 pandemic influenza A (H1N1)-related hospitalization and death among racial/ethnic groups in New Mexico. *American journal of public health*. 2011;101(9):1776-84.
374. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, Liu R, Ho KY, Chu KH, Watt CL, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JF, Wong SS, Zheng B, Chen H, Lau CC, Tse H, Cheng VC, Chan KH, Yuen KY. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(6):850-9.
375. Tramontana AR, George B, Hurt AC, Doyle JS, Langan K, Reid AB, Harper JM, Thursky K, Worth LJ, Dwyer DE, Morrissey CO, Johnson PD, Buising KL, Harrison SJ, Seymour JF, Ferguson PE, Wang B, Denholm JT, Cheng AC, Slavin M. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. *Emerging infectious diseases*. 2010;16(7):1068-75.
376. Tran D, Science M, Dix D, Portwine C, Zelcer S, Johnston DL, Yanofsky R, Gassas A, Ethier MC, Sung L. Pandemic (H1N1) 2009 influenza in Canadian pediatric cancer and hematopoietic stem cell transplant patients. *Influenza and other respiratory viruses*. 2012;6(6):e105-13.
377. Trimarchi H, Greloni G, Campolo-Girard V, Giannasi S, Pomeranz V, San-Roman E, Lombi F, Barcan L, Forrester M, Algranati S, Iriarte R, Rosa-Diez G. H1N1 infection and the kidney in critically ill patients. *Journal of nephrology*. 2010;23(6):725-31.
378. Tsagris V, Nika A, Kyriakou D, Kapetanakis I, Harahousou E, Stripeli F, Maltezos H, Tsofia M. Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit. *The Journal of hospital infection*. 2012;81(1):36-40.

379. Tsalik EL, Hendershot EF, Sangvai DG, Cunningham HM, Cunningham CK, Lopez-Marti MG, Purdy WK, Woods CW, Caram LB. Clinical presentation and response to treatment of novel influenza A H1N1 in a university-based summer camp population. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2010;47(3):286-8.
380. Tuna N, Karabay O, Yahyaoğlu M. Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment. *Indian journal of pharmacology*. 2012;44(6):780-3.
381. Varner MW, Rice MM, Anderson B, Tolosa JE, Sheffield J, Spong CY, Saade G, Peaceman AM, Louis JM, Wapner RJ, Tita AT, Sorokin Y, Blackwell SC, Prasad M, Thorp JM, Naresh A, Van Dorsten JP, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). Influenza-like illness in hospitalized pregnant and postpartum women during the 2009-2010 H1N1 pandemic. *Obstetrics and gynecology*. 2011;118(3):593-600.
382. Vasoo S, Crank CW, Singh K. Timely administration of antivirals for pandemic (H1N1) 2009 influenza. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;50(10):1428-9.
383. Viasus D, Paño-Pardo JR, Cordero E, Campins A, López-Medrano F, Villoslada A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Martínez-Montauti J, Torre-Cisneros J, Segura F, Carratalà J, Novel Influenza A (H1N1) Study Group, Spanish Network for Research in Infectious Diseases. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. *The Journal of infection*. 2011;62(3):193-9.
384. Viasus D, Paño-Pardo JR, Pachón J, Campins A, López-Medrano F, Villoslada A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Martínez-Montauti J, Torre-Cisneros J, Segura F, Gudiol F, Carratalà J, Novel Influenza A (H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2011;17(5):738-46.
385. Viasus D, Paño-Pardo JR, Pachón J, Riera M, López-Medrano F, Payeras A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Martínez-Montauti J, Torre-Cisneros J, Segura F, Gudiol F, Carratalà J, Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. *Medicine*. 2011;90(5):328-36.
386. Viasus D, Paño-Pardo JR, Pachón J, Riera M, López-Medrano F, Payeras A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Ortega L, Torre-Cisneros J, Segura F, Carratalà J, Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. *Chest*. 2011;140(4):1025-1032.
387. Wada K, Nishiura H, Kawana A. An epidemiological analysis of severe cases of the influenza A (H1N1) 2009 virus infection in Japan. *Influenza and other respiratory viruses*. 2010;4(4):179-86.

388. Wang CB, Chiu ML, Lin PC, Liang WM, Chen CY, Chang YJ, Wu TN, Wang JH, Sung FC. Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With Influenza Infection: An Asian Population Cohort Study. *Medicine*. 2015;94(27):e1070.
389. Weston KM, Truman G. An influenza prophylaxis clinic in a primary school: 24 hours from notification to protection. *New South Wales public health bulletin*. 2010;21(1-2):16-8.
390. Wilking H, Buda S, von der Lippe E, Altmann D, Krause G, Eckmanns T, Haas W. Mortality of 2009 pandemic influenza A(H1N1) in Germany. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2010;15(49).
391. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B, Chinese Critical Care Clinical Trial Group. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. *BMC infectious diseases*. 2010;10:256.
392. Xie HY, Yasseen AS, Xie RH, Fell DB, Sprague AE, Liu N, Smith GN, Walker MC, Wen SW. Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic. *American journal of obstetrics and gynecology*. 2013;208(4):293.e1-7.
393. Yamada T, Yamada T, Morikawa M, Cho K, Endo T, Sato SS, Saito T, Sengoku K, Minakami H. Pandemic (H1N1) 2009 in pregnant Japanese women in Hokkaido. *The journal of obstetrics and gynaecology research*. 2012;38(1):130-6.
394. Yamagishi T, Matsui T, Nakamura N, Oyama T, Taniguchi K, Aoki T, Hirakawa K, Okabe N. Onset and duration of symptoms and timing of disease transmission of 2009 influenza A (H1N1) in an outbreak in Fukuoka, Japan, June 2009. *Japanese journal of infectious diseases*. 2010;63(5):327-31.
395. Yang P, Deng Y, Pang X, Shi W, Li X, Tian L, Zhang Y, Wang X, Huang F, Raina MC, Wang Q. Severe, critical and fatal cases of 2009 H1N1 influenza in China. *The Journal of infection*. 2010;61(4):277-83.
396. Yang SG, Cao B, Liang LR, Li XL, Xiao YH, Cao ZX, Jia HY, Yu HJ, Xu Z, Gu L, Yang YD, Chen Y, Du WB, Yan XX, Liang ZA, Zhang W, Zhang CL, Chen W, Guo CP, Jiang XL, Yang M, Deng GM, Yu KJ, Hu K, Zou Q, Li LJ, Wang C, National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. *PLoS one*. 2012;7(1):e29652.
397. Yates L, Pierce M, Stephens S, Mill AC, Spark P, Kurinczuk JJ, Valappil M, Brocklehurst P, Thomas SH, Knight M. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. *Health technology assessment (Winchester, England)*. 2010;14(34):109-82.
398. Yokota RT, Skalinski LM, Igansi CN, de Souza LR, Iser BP, Reis PO, Barros EN, Macário EM, Bercini MA, Ranieri TM, Araújo WN. Risk factors for death from pandemic (H1N1) 2009, southern Brazil. *Emerging infectious diseases*. 2011;17(8):1467-71.
399. Yoo JW, Choi SH, Huh JW, Lim CM, Koh Y, Hong SB. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza. *Journal of medical virology*. 2015;87(10):1649-55.
400. Yoshino Y, Seo K, Koga I, Kitazawa T, Ota Y. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. *The clinical respiratory journal*. 2015;9(2):228-32.

401. Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, Ye M, Xiang N, Huai Y, Yuan Y, Jiang H, Zheng Y, Gargiullo P, Peng Z, Feng Y, Zheng J, Xu C, Zhang Y, Shu Y, Gao Z, Yang W, Wang Y. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;52(4):457-65.
402. Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, Guo X, Zheng Y, van Doorn HR, Farrar J, Gao Z, Feng Z, Wang Y, Yang W. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. *BMJ (Clinical research ed.)*. 2010;341:c4779.
403. Yung M, Slater A, Festa M, Williams G, Erickson S, Pettila V, Alexander J, Howe BD, Shekerdemian LS, Australia and New Zealand Intensive Care Influenza Investigators and the Paediatric Study Group and the Clinical Trials Group of the Australia New Zealand Intensive Care Society. Pandemic H1N1 in children requiring intensive care in Australia and New Zealand during winter 2009. *Pediatrics*. 2011;127(1):e156-63.
404. Zhang G, Xia Z, Liu Y, Li X, Tan X, Tian Y, Liang L, Nie G, Zhou B. Epidemiological and clinical features of 308 hospitalized patients with novel 2009 influenza A (H1N1) virus infection in China during the first pandemic wave. *Intervirology*. 2011;54(3):164-70.
405. Zhang PJ, Cao B, Li XL, Liang LR, Yang SG, Gu L, Xu Z, Hu K, Zhang HY, Yan XX, Huang WB, Chen W, Zhang JX, Li LJ, Wang C. Risk factors for adult death due to 2009 pandemic influenza A (H1N1) virus infection: a 2151 severe and critical cases analysis. *Chinese medical journal*. 2013;126(12):2222-8.
406. Zheng Y, He Y, Deng J, Lu Z, Wei J, Yang W, Tang Z, Li B, Zhang J, Wang L, Zhao H, Li X, Yu Z, Song P, Ma Y, Li Y, Li C. Hospitalized children with 2009 influenza a (H1N1) infection in Shenzhen, China, November-December 2009. *Pediatric pulmonology*. 2011;46(3):246-52.
407. del Rosal T, Baquero-Artigao F, Calvo C, Mellado MJ, Molina JC, Santos Mdel M, Cilleruelo MJ, Bueno M, Storch de Gracia P, Terol C, Roa MÁ, Piñeiro R, García López-Hortelano M, García-García ML, Rodríguez S, Penín M, Zarauza A, Alvarado F, de Blas A, Otheo E, Rodríguez A, Herreros ML, Tagarro A, Grande L, Ramos JT, Maté I, Muñoz C, Zafra MÁ, Romero-Gómez MP, Pérez-Fernández E, Delgado A, Casas I, Cabezas ME. Pandemic H1N1 influenza-associated hospitalizations in children in Madrid, Spain. *Influenza and other respiratory viruses*. 2011;5(6):e544-51.
408. te Beest DE, van Boven M, Bos ME, Stegeman A, Koopmans MP. Effectiveness of personal protective equipment and oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 2003. *Emerging infectious diseases*. 2010;16(10):1562-8.
409. van Gemert C, Hellard M, McBryde ES, Fielding J, Spelman T, Higgins N, Lester R, Vally H, Bergeri I. Intrahousehold transmission of pandemic (H1N1) 2009 virus, Victoria, Australia. *Emerging infectious diseases*. 2011;17(9):1599-607.
410. Wong JY, Kelly H, Cheung CM, Shiu EY, Wu P, Ni MY, Ip DK, Cowling BJ. Hospitalization Fatality Risk of Influenza A(H1N1)pdm09: A Systematic Review and Meta-Analysis. *American journal of epidemiology*. 2015;182(4):294-301